Publikationsserver der Universitätsbibliothek Marburg
Titel:Vergleich aktiv und passiv beschichteter Stents im Hinblick auf Restenoseprophylaxe - eine vergleichende tierexperimentelle Studie
Autor:Reinke, Julia Margaretha
Weitere Beteiligte: Kalinowski, Marc ( PD Dr.)
Veröffentlicht:2011
URI:https://archiv.ub.uni-marburg.de/diss/z2011/0550
URN: urn:nbn:de:hebis:04-z2011-05507
DOI: https://doi.org/10.17192/z2011.0550
DDC: Medizin
Titel (trans.):Active And Passive Stent Coating - is in-stent restenosis preventable?
Publikationsdatum:2011-08-22
Lizenz:https://rightsstatements.org/vocab/InC-NC/1.0/

Dokument

Schlagwörter:
bare-metal stent, stent, biomimicry, Neointima, Drug-eluting Stent, Sirolimus, restenosis, Nanocoating, neointima, Stent, Sirolimus, drug-eluting stent, Bare-Metal Stent, Restenose

Zusammenfassung:
Zusammenfassend kann aus dieser Studie entnommen werden, dass der getestete Ramapycin-Stent (+ Camouflage® Nanocoating) in der Lage ist die Neointimaproliferation und damit die Gefahr der Restenose signifikant zu senken. Weiterhin scheint dieser Stent durch seine antithrombogene Beschichtung in der Lage zu sein die Einheilung in die Gefäßwand zu verbessern, was möglicherweise durch die verbesserte vaskuläre Einheilung zu weniger Stentthrombosen führt. Die bessere Biokompatibilität und die damit verbundene verbesserte Einheilung könnten außerdem dazu führen, dass die momentan noch zwingend notwendige antikoagulative Therapie verkürzt oder herunterdosiert werden kann. Durch die Beschichtung mit Camouflage® Nanocoating ist es gelungen die erzielte Senkung der Restenosen durch eine besonders gute Biokompatibilität zu ergänzen. Gemeinsam sind diese beiden Komponenten möglicherweise in der Lage eine wiederholt verminderte Rate an Restenosen und Stentthrombosen zu erzielen. Weiteren Forschungsbedarf gibt es an vielen Stellen. Diese Studie ist als Pilotstudie anzusehen, die eine Möglichkeit der Verbesserung in der Therapie von Arteriosklerose im weitesten Sinne aufzeigt. Zukünftige Studien müssen evaluieren, ob 1. Sirolimus tatsächlich der optimale Wirkstoff ist, ob 2. das verwandte Polymer die beste Bioverträglichkeit hat und ob 3. die Eigenschaften des Stentgerüstes noch weiter optimiert werden können. Der Konkurrenzkampf zwischen PES und SES ist noch immer nicht endgültig entschieden und weitere Wirkstoffe wie Everolimus und Zotarolimus müssen ebenso evaluiert werden, wie neue Konzepte, die ohne Polymere auskommen oder komplett biodegenerable sind. Ebenso bieten DEB möglicherweise eine attraktive Alternative zu den bestehenden Therapiemöglichkeiten. Es sollten in Zukunft Studien durchgeführt werden, die eine genaue Evaluation der „neointimal coverage“ und der Inzidenz von Stenthrombosen vornehmen und auch deren molekulare Ursachen genauer erforschen, um die Überlegenheit des Rapamycin-Stents ( + Camouflage®) weiter zu festigen. Auch das Stentmaterial sollte noch einmal gesondert evaluiert werden. Es wären Studien sinnvoll, die BMS und DES mit dem Camouflage®-Stent vergleichen. Weiterhin sollte der Rapamycin-Stent (+Camouflage®) mit BMS und SES (ohne Camouflagebeschichtung) verglichen werden. Dies wäre sinnvoll, um die vielen Variablen zu minimieren und exaktere Daten für die Weiterentwicklung der DES zu generieren. Wenn die präklinische Phase abgeschlossen ist, muss das Konzept Rapamycin (+ Camouflage®) in der praktischen Anwendung am Patienten ebenfalls seine Wirksamkeit unter Beweis stellen. Erst dann können endgültige Aussagen zur Überlegenheit dieses Konzeptes gegenüber herkömmlichen Stents und konkurrierenden Verfahren gemacht werden.

Bibliographie / References

  1. MEREDITH, I. T., WORTHLEY, S., WHITBOURN, R., WALTERS, D. L., MCCLEAN, D., HORRIGAN, M., POPMA, J. J., CUTLIP, D. E., DEPAOLI, A., NEGOITA, M. & FITZGERALD, P. J. (2009) Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC Cardiovasc Interv, 2, 977-85.
  2. MORICE, M. C., COLOMBO, A., MEIER, B., SERRUYS, P., TAMBURINO, C., GUAGLIUMI, G., SOUSA, E. & STOLL, H. P. (2006) Sirolimus-vs paclitaxel- eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA, 295, 895-904.
  3. DAEMEN, J., WENAWESER, P., TSUCHIDA, K., ABRECHT, L., VAINA, S., MORGER, C., KUKREJA, N., JUNI, P., SIANOS, G., HELLIGE, G., VAN DOMBURG, R. T., HESS, O. M., BOERSMA, E., MEIER, B., WINDECKER, S. & SERRUYS, P. W. (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel- eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet, 369, 667-78.
  4. CUTLIP, D. E., WINDECKER, S., MEHRAN, R., BOAM, A., COHEN, D. J., VAN ES, G. A., STEG, P. G., MOREL, M. A., MAURI, L., VRANCKX, P., MCFADDEN, E., LANSKY, A., HAMON, M., KRUCOFF, M. W. & SERRUYS, P. W. (2007) Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 115, 2344-51.
  5. WENAWESER, P., DAEMEN, J., ZWAHLEN, M., VAN DOMBURG, R., JUNI, P., VAINA, S., HELLIGE, G., TSUCHIDA, K., MORGER, C., BOERSMA, E., KUKREJA, N., MEIER, B., SERRUYS, P. W. & WINDECKER, S. (2008) Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol, 52, 1134-40.
  6. COOK, S. & WINDECKER, S. (2009) Early stent thrombosis: past, present, and future. Circulation, 119, 657-9.
  7. SERRUYS, P. W., MORICE, M. C., KAPPETEIN, A. P., COLOMBO, A., HOLMES, D. R., MACK, M. J., STAHLE, E., FELDMAN, T. E., VAN DEN BRAND, M., BASS, E. J., VAN DYCK, N., LEADLEY, K., DAWKINS, K. D. & MOHR, F. W. (2009a) Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med, 360, 961-72.
  8. MARROQUIN, O. C., SELZER, F., MULUKUTLA, S. R., WILLIAMS, D. O., VLACHOS, H. A., WILENSKY, R. L., TANGUAY, J. F., HOLPER, E. M., ABBOTT, J. D., LEE, J. S., SMITH, C., ANDERSON, W. D., KELSEY, S. F. & KIP, K. E. (2008) A comparison of bare-metal and drug-eluting stents for off-label indications. N Engl J Med, 358, 342-52.
  9. MAURI, L., ORAV, E. J., CANDIA, S. C., CUTLIP, D. E. & KUNTZ, R. E. (2005a) Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation, 112, 2833-9.
  10. TEIRSTEIN, P. S. (2001) Living the dream of no restenosis. Circulation, 104, 1996-8.
  11. HONG, M. K., MINTZ, G. S., LEE, C. W., SONG, J. M., HAN, K. H., KANG, D. H., SONG, J. K., KIM, J. J., WEISSMAN, N. J., FEARNOT, N. E., PARK, S. W. & PARK, S. J. (2003) Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation, 107, 517-20.
  12. KOLODGIE, F. D., JOHN, M., KHURANA, C., FARB, A., WILSON, P. S., ACAMPADO, E., DESAI, N., SOON-SHIONG, P. & VIRMANI, R. (2002) Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation, 106, 1195-8.
  13. STAHLI, B. E., CAMICI, G. G., STEFFEL, J., AKHMEDOV, A., SHOJAATI, K., GRABER, M., LUSCHER, T. F. & TANNER, F. C. (2006) Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-Jun terminal NH2 kinase activation. Circ Res, 99, 149-55.
  14. SUZUKI, T., KOPIA, G., HAYASHI, S., BAILEY, L. R., LLANOS, G., WILENSKY, R., KLUGHERZ, B. D., PAPANDREOU, G., NARAYAN, P., LEON, M. B., YEUNG, A. C., TIO, F., TSAO, P. S., FALOTICO, R. & CARTER, A. J. (2001) Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation, 104, 1188-93.
  15. CARTER, A. J., SCOTT, D., BAILEY, L., HOOPES, T., JONES, R. & VIRMANI, R. (1999) Dose-response effects of 32P radioactive stents in an atherosclerotic porcine coronary model. Circulation, 100, 1548-54.
  16. LANSKY, A. J., ROUBIN, G. S., O'SHAUGHNESSY, C. D., MOORE, P. B., DEAN, L. S., RAIZNER, A. E., SAFIAN, R. D., ZIDAR, J. P., KERR, J. L., POPMA, J. J., MEHRAN, R., KUNTZ, R. E. & LEON, M. B. (2000) Randomized comparison of GR-II stent and Palmaz-Schatz stent for elective treatment of coronary stenoses. Circulation, 102, 1364-8.
  17. MEHRAN, R., DANGAS, G., ABIZAID, A. S., MINTZ, G. S., LANSKY, A. J., SATLER, L. F., PICHARD, A. D., KENT, K. M., STONE, G. W. & LEON, M. B. (1999) Angiographic patterns of in-stent restenosis: classification and implications for long- term outcome. Circulation, 100, 1872-8.
  18. CUTLIP, D. E., BAIM, D. S., HO, K. K., POPMA, J. J., LANSKY, A. J., COHEN, D. J., CARROZZA, J. P., JR., CHAUHAN, M. S., RODRIGUEZ, O. & KUNTZ, R. E. (2001) Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation, 103, 1967-71.
  19. KASTRATI, A., SCHOMIG, A., ELEZI, S., SCHUHLEN, H., DIRSCHINGER, J., HADAMITZKY, M., WEHINGER, A., HAUSLEITER, J., WALTER, H. & NEUMANN, F. J. (1997) Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol, 30, 1428-36.
  20. LOWE, H. C., OESTERLE, S. N. & KHACHIGIAN, L. M. (2002) Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol, 39, 183-93.
  21. MOORE, P., BARLIS, P., SPIRO, J., GHIMIRE, G., ROUGHTON, M., DI MARIO, C., WALLIS, W., ILSLEY, C., MITCHELL, A., MASON, M., KHARBANDA, R., VINCENT, P., SHERWIN, S. & DALBY, M. (2009) A randomized optical coherence tomography study of coronary stent strut coverage and luminal protrusion with rapamycin-eluting stents. JACC Cardiovasc Interv, 2, 437-44.
  22. LEFER, A. M., SCALIA, R. & LEFER, D. J. (2001) Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc Res, 49, 281-7.
  23. WARDEH, A. J., KNOOK, A. H., KAY, I. P., SABATE, M., COEN, V. L., FOLEY, D. P., HAMBURGER, J. N., LEVENDAG, P. C., VAN DER GIESSEN, W. J. & SERRUYS, P. W. (2001) Clinical and angiographical follow-up after implantation of a 6--12 microCi radioactive stent in patients with coronary artery disease. Eur Heart J, 22, 669-75.
  24. SCHELLER, B., HENNEN, B., POHL, A., SCHIEFFER, H. & MARKWIRTH, T. (2001) Acute and subacute stent occlusion; risk-reduction by ionic contrast media. Eur Heart J, 22, 385-91.
  25. WOHRLE, J., AL-KHAYER, E., GROTZINGER, U., SCHINDLER, C., KOCHS, M., HOMBACH, V. & HOHER, M. (2001) Comparison of the heparin coated vs the uncoated Jostent--no influence on restenosis or clinical outcome. Eur Heart J, 22, 1808-16.
  26. RENSING, B. J., VOS, J., SMITS, P. C., FOLEY, D. P., VAN DEN BRAND, M. J., VAN DER GIESSEN, W. J., DE FEIJTER, P. J. & SERRUYS, P. W. (2001) Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up. Eur Heart J, 22, 2125-30.
  27. SILBER, S., ALBERTSSON, P., AVILES, F. F., CAMICI, P. G., COLOMBO, A., HAMM, C., JORGENSEN, E., MARCO, J., NORDREHAUG, J. E., RUZYLLO, W., URBAN, P., STONE, G. W. & WIJNS, W. (2005) Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J, 26, 804-47.
  28. HOFMA, S. H., VAN DER GIESSEN, W. J., VAN DALEN, B. M., LEMOS, P. A., MCFADDEN, E. P., SIANOS, G., LIGTHART, J. M., VAN ESSEN, D., DE FEYTER, P. J. & SERRUYS, P. W. (2006) Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur Heart J, 27, 166-70.
  29. VAN BEUSEKOM, H. M., SAIA, F., ZINDLER, J. D., LEMOS, P. A., SWAGER-TEN HOOR, S. L., VAN LEEUWEN, M. A., DE FEIJTER, P. J., SERRUYS, P. W. & VAN DER GIESSEN, W. J. (2007) Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus. Eur Heart J, 28, 974-9.
  30. SCHULZ, S., SCHUSTER, T., MEHILLI, J., BYRNE, R. A., ELLERT, J., MASSBERG, S., GOEDEL, J., BRUSKINA, O., ULM, K., SCHOMIG, A. & KASTRATI, A. (2009) Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal, 30, 2714-2721.
  31. ROIRON, C., SANCHEZ, P., BOUZAMONDO, A., LECHAT, P. & MONTALESCOT, G. (2006) Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart, 92, 641-9.
  32. YANG, X., CAI, B., SCIACCA, R. R. & CANNON, P. J. (1994) Inhibition of inducible nitric oxide synthase in macrophages by oxidized low-density lipoproteins. Circ Res, 74, 318-28.
  33. VALGIMIGLI, M., PERCOCO, G., MALAGUTTI, P., CAMPO, G., FERRARI, F., BARBIERI, D., CICCHITELLI, G., MCFADDEN, E. P., MERLINI, F., ANSANI, L., GUARDIGLI, G., BETTINI, A., PARRINELLO, G., BOERSMA, E. & FERRARI, R. (2005a) Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA, 293, 2109-17.
  34. STETTLER, C., WANDEL, S., ALLEMANN, S., KASTRATI, A., MORICE, M. C., SCHOMIG, A., PFISTERER, M. E., STONE, G. W., LEON, M. B., DE LEZO, J. S., GOY, J. J., PARK, S. J., SABATE, M., SUTTORP, M. J., KELBAEK, H., SPAULDING, C., MENICHELLI, M., VERMEERSCH, P., DIRKSEN, M. T., CERVINKA, P., PETRONIO, A. S., NORDMANN, A. J., DIEM, P., MEIER, B., ZWAHLEN, M., REICHENBACH, S., TRELLE, S., WINDECKER, S. & JUNI, P. (2007) Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet, 370, 937-48.
  35. TANZILLI, G., GRECO, C., PELLICCIA, F., PASCERI, V., BARILLA, F., PARAVATI, V., PANNITTERI, G., GAUDIO, C. & MANGIERI, E. (2009) Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol, 104, 1357-61.
  36. CHIEFFO, A., STANKOVIC, G., BONIZZONI, E., TSAGALOU, E., IAKOVOU, I., MONTORFANO, M., AIROLDI, F., MICHEV, I., SANGIORGI, M. G., CARLINO, M., VITRELLA, G. & COLOMBO, A. (2005) Early and mid-term results of drug- eluting stent implantation in unprotected left main. Circulation, 111, 791-5.
  37. URBAN, P., GERSHLICK, A. H., GUAGLIUMI, G., GUYON, P., LOTAN, C., SCHOFER, J., SETH, A., SOUSA, J. E., WIJNS, W., BERGE, C., DEME, M. & STOLL, H. P. (2006) Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation, 113, 1434-41.
  38. REGAR, E., SERRUYS, P. W., BODE, C., HOLUBARSCH, C., GUERMONPREZ, J. L., WIJNS, W., BARTORELLI, A., CONSTANTINI, C., DEGERTEKIN, M., TANABE, K., DISCO, C., WUELFERT, E. & MORICE, M. C. (2002) Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon- Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation, 106, 1949-56.
  39. MEREDITH, I. T., WORTHLEY, S. G., WHITBOURN, R., WALTERS, D., MCCLEAN, D., ORMISTON, J., HORRIGAN, M., WILKINS, G. T., HENDRIKS, R., MATSIS, P., MULLER, D. & CUTLIP, D. E. (2010) Long-term clinical outcomes with the next- generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial. EuroIntervention, 5, 692-7.
  40. CANOUI-POITRINE, F., JEANBLANC, G., ALBERTI, C., ARMOOGUM, P., CEBRIAN, A., CARRIE, D., HENRY, P., TEIGER, E., SLAMA, M., SPAULDING, C. & DURAND-ZALESKI, I. (2009) Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial. Appl Health Econ Health Policy, 7, 19-29.
  41. NEYT, M., VAN BRABANDT, H., DEVRIESE, S. & DE LAET, C. (2009) Cost- effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Health Policy, 91, 107-20.
  42. SERRUYS, P. W., ONUMA, Y., GARG, S., VRANCKX, P., DE BRUYNE, B., MORICE, M. C., COLOMBO, A., MACAYA, C., RICHARDT, G., FAJADET, J., HAMM, C., SCHUIJER, M., RADEMAKER, T., WITTEBOLS, K. & STOLL, H. P. (2010b) 5- year clinical outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the sirolimus-eluting stent in the treatment of patients with multivessel de novo coronary artery lesions. J Am Coll Cardiol, 55, 1093-101.
  43. WATAHA, J. C., LOCKWOOD, P. E., MAREK, M. & GHAZI, M. (1999) Ability of Ni- containing biomedical alloys to activate monocytes and endothelial cells in vitro. J Biomed Mater Res, 45, 251-7.
  44. LI, J., JABARA, R., PENDYALA, L., OTSUKA, Y., SHINKE, T., HOU, D., ROBINSON, K. & CHRONOS, N. (2008) Abnormal vasomotor function of porcine coronary arteries distal to sirolimus-eluting stents. JACC Cardiovasc Interv, 1, 279-85.
  45. SMITH, S. C., JR., DOVE, J. T., JACOBS, A. K., KENNEDY, J. W., KEREIAKES, D., KERN, M. J., KUNTZ, R. E., POPMA, J. J., SCHAFF, H. V., WILLIAMS, D. O., GIBBONS, R. J., ALPERT, J. P., EAGLE, K. A., FAXON, D. P., FUSTER, V., GARDNER, T. J., GREGORATOS, G. & RUSSELL, R. O. (2001) ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol, 37, 2215-39.
  46. SMITH, S. C., FELDMAN, T. E., HIRSHFELD, J. W., JACOBS, A. K., KERN, M. J., KING, S. B., MORRISON, D. A., O'NEILL, W. W., SCHAFF, H. V., WHITLOW, P. L., WILLIAMS, D. O. & COMM, A. A. S. W. (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention -Summary article -A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 guidelines for percutaneous coronary intervention). Journal of the American College of Cardiology, 47, 216-235.
  47. LEON, M. B., BAIM, D. S., POPMA, J. J., GORDON, P. C., CUTLIP, D. E., HO, K. K., GIAMBARTOLOMEI, A., DIVER, D. J., LASORDA, D. M., WILLIAMS, D. O., POCOCK, S. J. & KUNTZ, R. E. (1998) A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med, 339, 1665-71.
  48. WALTERS, D. L., HARDING, S. A., WALSH, C. R., WONG, P., POMERANTSEV, E. & JANG, I. K. (2002) Acute coronary syndrome is a common clinical presentation of in- stent restenosis. Am J Cardiol, 89, 491-4.
  49. MURAKAMI, D., TAKANO, M., YAMAMOTO, M., INAMI, S., OHBA, T., SEINO, Y. & MIZUNO, K. (2009) Advanced neointimal growth is not associated with a low risk of in-stent thrombus. Optical coherence tomographic findings after first-generation drug- eluting stent implantation. Circ J, 73, 1627-34.
  50. YAO, F., VISOVATTI, S., JOHNSON, C. S., CHEN, M., SLAMA, J., WENGER, A. & ERIKSSON, E. (2001) Age and growth factors in porcine full-thickness wound healing. Wound Repair Regen, 9, 371-7.
  51. SATA, M., MAEJIMA, Y., ADACHI, F., FUKINO, K., SAIURA, A., SUGIURA, S., AOYAGI, T., IMAI, Y., KURIHARA, H., KIMURA, K., OMATA, M., MAKUUCHI, M., HIRATA, Y. & NAGAI, R. (2000) A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol, 32, 2097-104.
  52. KASTRATI, A., MEHILLI, J., PACHE, J., KAISER, C., VALGIMIGLI, M., KELBAEK, H., MENICHELLI, M., SABATE, M., SUTTORP, M. J., BAUMGART, D., SEYFARTH, M., PFISTERER, M. E. & SCHOMIG, A. (2007) Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 356, 1030-9. KASTRATI, A., MEHILLI, J., VON BECKERATH, N., DIBRA, A., HAUSLEITER, J., PACHE, J., SCHUHLEN, H., SCHMITT, C., DIRSCHINGER, J. & SCHOMIG, A. (2005b) Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA, 293, 165-71.
  53. POPMA, J. & ALMONACID, A. (2009) Angiographic Markers of Restenosis after Drug- Eluting Stent Implantation: Surrogates for Late Clinical Outcomes? J Interven Cardiol 2009;22:S64–S71.
  54. TWINE, C. P., COULSTON, J., SHANDALL, A. & MCLAIN, A. D. (2009) Angioplasty versus stenting for superficial femoral artery lesions. Cochrane Database Syst Rev, CD006767.
  55. KRUCOFF, M. W., KEREIAKES, D. J., PETERSEN, J. L., MEHRAN, R., HASSELBLAD, V., LANSKY, A. J., FITZGERALD, P. J., GARG, J., TURCO, M. A., SIMONTON, C. A., 3RD, VERHEYE, S., DUBOIS, C. L., GAMMON, R., BATCHELOR, W. B., O'SHAUGHNESSY, C. D., HERMILLER, J. B., JR., SCHOFER, J., BUCHBINDER, M. & WIJNS, W. (2008) A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol, 51, 1543-52.
  56. MULDOWNEY, J. A., 3RD, STRINGHAM, J. R., LEVY, S. E., GLEAVES, L. A., EREN, M., PIANA, R. N. & VAUGHAN, D. E. (2007) Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. Arterioscler Thromb Vasc Biol, 27, 400-6.
  57. SMITH, E. J. & ROTHMAN, M. T. (2003) Antiproliferative coatings for the treatment of coronary heart disease:. what are the targets and which are the tools? J Interv Cardiol, 16, 475-83.
  58. NIEVELSTEIN-POST, P., MOTTINO, G., FOGELMAN, A. & FRANK, J. (1994) An ultrastructural study of lipoprotein accumulation in cardiac valves of the rabbit. Arterioscler Thromb, 14, 1151-61.
  59. HOFF, H. F., HEIDEMAN, C. L. & GAUBATZ, J. W. (1977a) Apolipoprotein B (apoB) retention in atherosclerotic intracranial arteries. Stroke, 8, 366-70.
  60. STONE, G. W., ELLIS, S. G., COX, D. A., HERMILLER, J., O'SHAUGHNESSY, C., MANN, J. T., TURCO, M., CAPUTO, R., BERGIN, P., GREENBERG, J., POPMA, J. J. & RUSSELL, M. E. (2004) A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med, 350, 221-31.
  61. KIM, J. W., SEO, H. S., PARK, J. H., NA, J. O., CHOI, C. U., LIM, H. E., KIM, E. J., RHA, S. W., PARK, C. G. & OH, D. J. (2009d) A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. J Am Coll Cardiol, 53, 1653-9.
  62. SERRUYS, P. W., RUYGROK, P., NEUZNER, J., PIEK, J. J., SETH, A., SCHOFER, J. J., RICHARDT, G., WIEMER, M., CARRIE, D., THUESEN, L., BOONE, E., MIQUEL-HERBERT, K. & DAEMEN, J. (2006) A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention, 2, 286-94.
  63. SCHOMIG, A., NEUMANN, F. J., KASTRATI, A., SCHUHLEN, H., BLASINI, R., HADAMITZKY, M., WALTER, H., ZITZMANN-ROTH, E. M., RICHARDT, G., ALT, E., SCHMITT, C. & ULM, K. (1996) A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med, 334, 1084-9.
  64. LEE, S. W., PARK, S. W., KIM, Y. H., YUN, S. C., PARK, D. W., LEE, C. W., HONG, M. K., RHEE, K. S., CHAE, J. K., KO, J. K., PARK, J. H., LEE, J. H., CHOI, S. W., JEONG, J. O., SEONG, I. W., CHO, Y. H., LEE, N. H., KIM, J. H., CHUN, K. J., KIM, H. S. & PARK, S. J. (2008) A randomized comparison of sirolimus-versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am Coll Cardiol, 52, 727-33.
  65. BROWN, M. S. & GOLDSTEIN, J. L. (1986) A receptor-mediated pathway for cholesterol homeostasis. Science, 232, 34-47.
  66. SERRUYS, P. W. & DAEMEN, J. (2007) Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation, 115, 1433-9; discussion 1439. SERRUYS, P. W., DAEMEN, J., MORICE, M. C., DE BRUYNE, B., COLOMBO, A., MACAYA, C., RICHARDT, G., FAJADET, J., HAMM, C., DAWKINS, K. D., VRANCKX, P., BRESSERS, M., VAN DOMBURG, R., SCHUIJER, M., WITTEBOLS, K., PIETERS, M. & STOLL, H. P. (2008) Three-year follow-up of the ARTS-II# -sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroIntervention, 3, 450-9.
  67. MINTZ, G. S., POPMA, J. J., PICHARD, A. D., KENT, K. M., SATLER, L. F., WONG, C., HONG, M. K., KOVACH, J. A. & LEON, M. B. (1996) Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 94, 35-43.
  68. SERRUYS, P. W., ONG, A. T., MORICE, M. C., DE BRUYNE, B., COLOMBO, A., MACAYA, C., RICHARDT, G., FAJADET, J., HAMM, C., DAWKINS, K., O'MALLEY, A. J., BRESSERS, M. & DONOHOE, D. (2005) Arterial Revascularisation Therapies Study Part II -Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. EuroIntervention, 1, 147- 56.
  69. MASUDA, J. & ROSS, R. (1990a) Atherogenesis during low level hypercholesterolemia in the nonhuman primate. I. Fatty streak formation. Arteriosclerosis, 10, 164-77.
  70. ROSS, R. (1999) Atherosclerosis--an inflammatory disease. N Engl J Med, 340, 115-26.
  71. BROWN, M. S. & GOLDSTEIN, J. L. (1990) Atherosclerosis. Scavenging for receptors. Nature, 343, 508-9.
  72. GARG, P., COHEN, D. J., GAZIANO, T. & MAURI, L. (2008) Balancing the risks of restenosis and stent thrombosis in bare-metal versus drug-eluting stents: results of a decision analytic model. J Am Coll Cardiol, 51, 1844-53.
  73. CHEN, M. S., JOHN, J. M., CHEW, D. P., LEE, D. S., ELLIS, S. G. & BHATT, D. L. (2006) Bare metal stent restenosis is not a benign clinical entity. Am Heart J, 151, 1260-4.
  74. Beginn einer experimentellen Promotion im Fach Radiologie zur Fragestellung der Effektivität von medikamentenbeschichteten Stents Ab 2006
  75. MARX, S. O. & MARKS, A. R. (2001) Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation, 104, 852-5.
  76. STEINBERG, D., PARTHASARATHY, S., CAREW, T. E., KHOO, J. C. & WITZTUM, J. L. (1989) Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, 320, 915-24.
  77. CUTLIP, D. E., CHHABRA, A. G., BAIM, D. S., CHAUHAN, M. S., MARULKAR, S., MASSARO, J., BAKHAI, A., COHEN, D. J., KUNTZ, R. E. & HO, K. K. (2004) Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation, 110, 1226-30.
  78. WILLIAMS, D. O. & ABBOTT, J. D. (2005) Bifurcation intervention: is it crush time yet? J Am Coll Cardiol, 46, 621-4.
  79. NIEMELA, K. O. (2008) Biodegradable coating for drug-eluting stents--more than a facelift? Eur Heart J, 29, 1930-1.
  80. DANI, S., KUKREJA, N., PARIKH, P., JOSHI, H., PRAJAPATI, J., JAIN, S., THANVI, S., SHAH, B. & DUTTA, J. P. (2008) Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. EuroIntervention, 4, 59-63.
  81. WINDECKER, S., SERRUYS, P. W., WANDEL, S., BUSZMAN, P., TRZNADEL, S., LINKE, A., LENK, K., ISCHINGER, T., KLAUSS, V., EBERLI, F., CORTI, R., WIJNS, W., MORICE, M. C., DI MARIO, C., DAVIES, S., VAN GEUNS, R. J., EERDMANS, P., VAN ES, G. A., MEIER, B. & JUNI, P. (2008) Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet, 372, 1163-73.
  82. DE WINTER, R. (2009) Can pro-healing stent make a difference? Final 12-months outcomes from the e-HEALING 5.000 patient registry using the EPC-coated Genous stent. Paper presented at: Transcatherter Cardiovascular Therapeutics; September 22, 2009; San Francisco, CA.
  83. SMOUSE, B. (2005) Changes in the femoral arteries during joint movement before and after stent placement in the cadaver model. Presented at the Society of Interventional Radiology 2005 Annual Meeting, New Orleans, LA.
  84. GE, L., AIROLDI, F., IAKOVOU, I., COSGRAVE, J., MICHEV, I., SANGIORGI, G. M., MONTORFANO, M., CHIEFFO, A., CARLINO, M., CORVAJA, N. & COLOMBO, A. (2005) Clinical and angiographic outcome after implantation of drug-eluting stents in bifurcation lesions with the crush stent technique: importance of final kissing balloon post-dilation. J Am Coll Cardiol, 46, 613-20.
  85. SINGH, M., GERSH, B. J., MCCLELLAND, R. L., HO, K. K., WILLERSON, J. T., PENNY, W. F. & HOLMES, D. R., JR. (2004) Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) trial. Circulation, 109, 2727- 31.
  86. MERCADO, N., BOERSMA, E., WIJNS, W., GERSH, B. J., MORILLO, C. A., DE VALK, V., VAN ES, G. A., GROBBEE, D. E. & SERRUYS, P. W. (2001) Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol, 38, 645-52.
  87. LEMOS, P. A., HOYE, A., GOEDHART, D., ARAMPATZIS, C. A., SAIA, F., VAN DER GIESSEN, W. J., MCFADDEN, E., SIANOS, G., SMITS, P. C., HOFMA, S. H., DE FEYTER, P. J., VAN DOMBURG, R. T. & SERRUYS, P. W. (2004a) Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus- eluting stent implantation in complex patients: an evaluation from the Rapamycin- Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation, 109, 1366-70.
  88. MACHAN, L. (2006) Clinical experience and applications of drug-eluting stents in the noncoronary vasculature, bile duct and esophagus. Adv Drug Deliv Rev, 58, 447-62.
  89. NIENABER, C. A., AKIN, I., SCHNEIDER, S., SENGES, J., FETSCH, T., TEBBE, U., WILLICH, S. N., STUMPF, J., SABIN, G. V., SILBER, S., RICHARDT, G. & KUCK, K. H. (2009) Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry). Am J Cardiol, 104, 1362-9.
  90. WIN, H. K., CALDERA, A. E., MARESH, K., LOPEZ, J., RIHAL, C. S., PARIKH, M. A., GRANADA, J. F., MARULKAR, S., NASSIF, D., COHEN, D. J. & KLEIMAN, N. S. (2007) Clinical outcomes and stent thrombosis following off-label use of drug- eluting stents. JAMA, 297, 2001-9.
  91. CUTLIP, D. E., CHAUHAN, M. S., BAIM, D. S., HO, K. K., POPMA, J. J., CARROZZA, J. P., COHEN, D. J. & KUNTZ, R. E. (2002) Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol, 40, 2082-9.
  92. WAKSMAN, R. & PAKALA, R. (2009) Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. . EuroIntervention Supplement Vol. 5 (Supplement F) F36-F42 WALTER, D. H., SCHACHINGER, V., ELSNER, M., MACH, S., AUCH-SCHWELK, W. & ZEIHER, A. M. (2000) Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol, 85, 962-8.
  93. MCKEE, S. A., APPLEGATE, R. J., HOYLE, J. R., SACRINTY, M. T., KUTCHER, M. A. & SANE, D. C. (2007) Cocaine use is associated with an increased risk of stent thrombosis after percutaneous coronary intervention. Am Heart J, 154, 159-64.
  94. SIMONTON, C. A., BRODIE, B., CHEEK, B., KRAININ, F., METZGER, C., HERMILLER, J., JUK, S., DUFFY, P., HUMPHREY, A., NUSSBAUM, M. & LAURENT, S. (2007) Comparative clinical outcomes of paclitaxel-and sirolimus- eluting stents: results from a large prospective multicenter registry--STENT Group. J Am Coll Cardiol, 50, 1214-22.
  95. STONE, G. W., MIDEI, M., NEWMAN, W., SANZ, M., HERMILLER, J. B., WILLIAMS, J., FARHAT, N., MAHAFFEY, K. W., CUTLIP, D. E., FITZGERALD, P. J., SOOD, P., SU, X. & LANSKY, A. J. (2008) Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA, 299, 1903-13.
  96. RUEF, J., STORGER, H., SCHWARZ, F. & HAASE, J. (2008) Comparison of a polymer- free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. Catheter Cardiovasc Interv, 71, 333- 9.
  97. WILSON, G. J., NAKAZAWA, G., SCHWARTZ, R. S., HUIBREGTSE, B., POFF, B., HERBST, T. J., BAIM, D. S. & VIRMANI, R. (2009) Comparison of inflammatory response after implantation of sirolimus-and paclitaxel-eluting stents in porcine coronary arteries. Circulation, 120, 141-9, 1-2.
  98. JUWANA, Y. B., SURYAPRANATA, H., OTTERVANGER, J. P., DE LUCA, G., VAN'T HOF, A. W., DAMBRINK, J. H., DE BOER, M. J., GOSSELINK, A. T. & HOORNTJE, J. C. (2009) Comparison of rapamycin-and paclitaxel-eluting stents in patients undergoing primary percutaneous coronary intervention for ST-elevation myocardial infarction. Am J Cardiol, 104, 205-9.
  99. MAENG, M., JENSEN, L. O., GALLOE, A. M., THAYSSEN, P., CHRISTIANSEN, E. H., HANSEN, K. N., HELQVIST, S., BOTKER, H. E., LASSEN, J. F. & THUESEN, L. (2009) Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol, 103, 345-9.
  100. CREMERS, B., BIEDERMANN, M., MAHNKOPF, D., BOHM, M. & SCHELLER, B. (2009a) Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol, 98, 325-30.
  101. KANDZARI, D. E., LEON, M. B., POPMA, J. J., FITZGERALD, P. J., O'SHAUGHNESSY, C., BALL, M. W., TURCO, M., APPLEGATE, R. J., GURBEL, P. A., MIDEI, M. G., BADRE, S. S., MAURI, L., THOMPSON, K. P., LENARZ, L. A. & KUNTZ, R. E. (2006) Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol, 48, 2440-7.
  102. GLAGOV, S., WEISENBERG, E., ZARINS, C. K., STANKUNAVICIUS, R. & KOLETTIS, G. J. (1987) Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med, 316, 1371-5.
  103. COSTA, R. (2010) Complex patients with coronary artery disease treated with the novel Supralimus Sirolimus-eluting Stents: preliminary results of the prospective, multicentre, non-randomised E-Series trial. paper presented at: EuroPCR; May 19-22, 2010; Barcelona, Spain.
  104. ROUKOZ, H., BAVRY, A. A., SARKEES, M. L., MOOD, G. R., KUMBHANI, D. J., RABBAT, M. G. & BHATT, D. L. (2009) Comprehensive meta-analysis on drug- eluting stents versus bare-metal stents during extended follow-up. Am J Med, 122, 581 e1-10.
  105. LEMOS, P. A., SAIA, F., LIGTHART, J. M., ARAMPATZIS, C. A., SIANOS, G., TANABE, K., HOYE, A., DEGERTEKIN, M., DAEMEN, J., MCFADDEN, E., HOFMA, S., SMITS, P. C., DE FEYTER, P., VAN DER GIESSEN, W. J., VAN DOMBURG, R. T. & SERRUYS, P. W. (2003a) Coronary restenosis after sirolimus- eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circulation, 108, 257-60.
  106. MORENO, R., FERNANDEZ, C., ALFONSO, F., HERNANDEZ, R., PEREZ-VIZCAYNO, M. J., ESCANED, J., SABATE, M., BANUELOS, C., ANGIOLILLO, D. J., AZCONA, L. & MACAYA, C. (2004) Coronary stenting versus balloon angioplasty in small vessels: a meta-analysis from 11 randomized studies. J Am Coll Cardiol, 43, 1964-72.
  107. CARTER, A. J., LAIRD, J. R., KUFS, W. M., BAILEY, L., HOOPES, T. G., REEVES, T., FARB, A. & VIRMANI, R. (1996b) Coronary stenting with a novel stainless steel balloon-expandable stent: determinants of neointimal formation and changes in arterial geometry after placement in an atherosclerotic model. J Am Coll Cardiol, 27, 1270-7.
  108. GARG, S. & SERRUYS, P. W. (2010a) Coronary stents: current status. J Am Coll Cardiol, 56, S1-42.
  109. GARG, S. & SERRUYS, P. W. (2010b) Coronary stents: looking forward. J Am Coll Cardiol, 56, S43-78.
  110. RODRIGUEZ, A. E., MIERES, J., FERNANDEZ-PEREIRA, C., VIGO, C. F., RODRIGUEZ-ALEMPARTE, M., BERROCAL, D., GRINFELD, L. & PALACIOS, I. (2006) Coronary stent thrombosis in the current drug-eluting stent era: insights from the ERACI III trial. J Am Coll Cardiol, 47, 205-7.
  111. KUCHULAKANTI, P. K., CHU, W. W., TORGUSON, R., OHLMANN, P., RHA, S. W., CLAVIJO, L. C., KIM, S. W., BUI, A., GEVORKIAN, N., XUE, Z., SMITH, K., FOURNADJIEVA, J., SUDDATH, W. O., SATLER, L. F., PICHARD, A. D., KENT, K. M. & WAKSMAN, R. (2006) Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation, 113, 1108-13.
  112. BRUNNER-LA ROCCA, H. P., KAISER, C., BERNHEIM, A., ZELLWEGER, M. J., JEGER, R., BUSER, P. T., OSSWALD, S. & PFISTERER, M. (2007) Cost- effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitats Trial (BASKET): an 18-month analysis. Lancet, 370, 1552-9.
  113. SHUCHMAN, M. (2007) Debating the risks of drug-eluting stents. N Engl J Med, 356, 325-8. SIGNORE, P. E., MACHAN, L. S., JACKSON, J. K., BURT, H., BROMLEY, P., WILSON, J. E. & MCMANUS, B. M. (2001) Complete inhibition of intimal hyperplasia by perivascular delivery of paclitaxel in balloon-injured rat carotid arteries. J Vasc Interv Radiol, 12, 79-88.
  114. WEINBERGER, J. (2005) Diagnosis and prevention of atherosclerotic cerebral infarction. CNS Spectr, 10, 553-64.
  115. CHEN, S. L., YE, F., ZHANG, J. J., LIU, Z. Z., SHAN, S. J., SUN, X. W., ZHANG, A. P., CHEN, J. G., XU, Y. W., YANG, S., CHEN, F. & LUO, W. P. (2009) Different edge effects of paclitaxel-and sirolimus-eluting stents on proximal and distal edges in patients with unstable angina: serial intravascular ultrasound analysis. Chin Med J (Engl), 122, 1603-9.
  116. MEHRABIAN, M., DEMER, L. L. & LUSIS, A. J. (1991) Differential accumulation of intimal monocyte-macrophages relative to lipoproteins and lipofuscin corresponds to hemodynamic forces on cardiac valves in mice. Arterioscler Thromb, 11, 947-57.
  117. MARTINEZ-ELBAL, L., RUIZ-NODAR, J. M., ZUECO, J., LOPEZ-MINGUEZ, J. R., MOREU, J., CALVO, I., RAMIREZ, J. A., ALONSO, M., VAZQUEZ, N., LEZAUN, R. & RODRIGUEZ, C. (2002) Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. DIrect Stenting of COronary Arteries. Eur Heart J, 23, 633-40.
  118. YOSHITOMI, Y., KOJIMA, S., YANO, M., SUGI, T., MATSUMOTO, Y., SAOTOME, M., TANAKA, K., ENDO, M. & KURAMOCHI, M. (2001) Does stent design affect probability of restenosis? A randomized trial comparing Multilink stents with GFX stents. Am Heart J, 142, 445-51.
  119. CREMERS, B., SPECK, U., KAUFELS, N., MAHNKOPF, D., KUHLER, M., BOHM, M. & SCHELLER, B. (2009b) Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost, 101, 201-6.
  120. SILBER, S., BORGGREFE, M., BOHM, M., HOFFMEISTER, H. M., DIETZ, R., ERTL, G. & HEUSCH, G. (2008) [Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK]. Clin Res Cardiol, 97, 548-63.
  121. SUBRAMANIAM, K. G. & AKHUNJI, Z. (2009) Drug eluting stent induced coronary artery aneurysm repair by exclusion. Where are we headed? Eur J Cardiothorac Surg, 36, 203-5.
  122. HILL, R. A., DUNDAR, Y., BAKHAI, A., DICKSON, R. & WALLEY, T. (2004) Drug- eluting stents: an early systematic review to inform policy. Eur Heart J, 25, 902-19. HIRAYAMA, A., KODAMA, K., ADACHI, T., NANTO, S., OHARA, T., TAMAI, H., KYO, E., ISSHIKI, T. & OCHIAI, M. (2000) Angiographic and clinical outcome of a new self-expanding intracoronary stent (RADIUS): results from multicenter experience in Japan. Catheter Cardiovasc Interv, 49, 401-7.
  123. VIRMANI, R., KOLODGIE, F. D., FARB, A. & LAFONT, A. (2003) Drug eluting stents: are human and animal studies comparable? Heart, 89, 133-8.
  124. LEMOS, P. A., SERRUYS, P. W. & SOUSA, J. E. (2003b) Drug-eluting stents: cost versus clinical benefit. Circulation, 107, 3003-7.
  125. SLAVIN, L., CHHABRA, A. & TOBIS, J. M. (2007) Drug-eluting stents: preventing restenosis. Cardiol Rev, 15, 1-12.
  126. VAN DER HOEVEN, B. L., PIRES, N. M., WARDA, H. M., OEMRAWSINGH, P. V., VAN VLIJMEN, B. J., QUAX, P. H., SCHALIJ, M. J., VAN DER WALL, E. E. & JUKEMA, J. W. (2005) Drug-eluting stents: results, promises and problems. Int J Cardiol, 99, 9-17.
  127. PARRY, T. J., BROSIUS, R., THYAGARAJAN, R., CARTER, D., ARGENTIERI, D., FALOTICO, R. & SIEKIERKA, J. (2005) Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol, 524, 19-29.
  128. DE LA TORRE-HERNANDEZ, J. M., ALFONSO, F., HERNANDEZ, F., ELIZAGA, J., SANMARTIN, M., PINAR, E., LOZANO, I., VAZQUEZ, J. M., BOTAS, J., DE PRADO, A. P., HERNANDEZ, J. M., SANCHIS, J., NODAR, J. M., GOMEZ- JAUME, A., LARMAN, M., DIARTE, J. A., RODRIGUEZ-COLLADO, J., RUMOROSO, J. R., LOPEZ-MINGUEZ, J. R. & MAURI, J. (2008) Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol, 51, 986-90.
  129. COLOMBO, A. & CHIEFFO, A. (2007) Drug-eluting stent update 2007: part III: Technique and unapproved/unsettled indications (left main, bifurcations, chronic total occlusions, small vessels and long lesions, saphenous vein grafts, acute myocardial infarctions, and multivessel disease). Circulation, 116, 1424-32.
  130. WAKSMAN, R., ERBEL, R., DI MARIO, C., BARTUNEK, J., DE BRUYNE, B., EBERLI, F. R., ERNE, P., HAUDE, M., HORRIGAN, M., ILSLEY, C., BOSE, D., BONNIER, H., KOOLEN, J., LUSCHER, T. F. & WEISSMAN, N. J. (2009) Early-and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries. JACC Cardiovasc Interv, 2, 312-20.
  131. TU, J. V., BOWEN, J., CHIU, M., KO, D. T., AUSTIN, P. C., HE, Y., HOPKINS, R., TARRIDE, J. E., BLACKHOUSE, G., LAZZAM, C., COHEN, E. A. & GOEREE, R. (2007) Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med, 357, 1393-402.
  132. DEMER, L. L. (1991) Effect of calcification on in vivo mechanical response of rabbit arteries to balloon dilation. Circulation, 83, 2083-93.
  133. TANABE, Y., ITO, E., NAKAGAWA, I. & SUZUKI, K. (2001) Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. Int J Cardiol, 78, 285-91.
  134. PARK, S. W., LEE, C. W., KIM, H. S., LEE, N. H., NAH, D. Y., HONG, M. K., KIM, J. J. & PARK, S. J. (2000) Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol, 86, 499-503.
  135. KOZUMA, K., HARA, K., YAMASAKI, M., MORINO, Y., AYABE, S., KURODA, Y., TANABE, K., IKARI, Y. & TAMURA, T. (2001) Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. Am Heart J, 141, 124-30.
  136. CARTER, A. J., LAIRD, J. R., BAILEY, L. R., HOOPES, T. G., FARB, A., FISCHELL, D. R., FISCHELL, R. E., FISCHELL, T. A. & VIRMANI, R. (1996a) Effects of endovascular radiation from a beta-particle-emitting stent in a porcine coronary restenosis model. A dose-response study. Circulation, 94, 2364-8.
  137. MANGIN, E. L., JR., KUGIYAMA, K., NGUY, J. H., KERNS, S. A. & HENRY, P. D. (1993) Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res, 72, 161-6.
  138. e-mail reinkejm@googlemail.com oder reinke.julia@mh-hannover.de Familienstand verheiratet Ausbildung ab Juli 2011 Assistenzärztin in der Unfallchirurgie, MHH Rotation für 6 Monate seit Januar 2011
  139. TOBOREK, M. & KAISER, S. (1999) Endothelial cell functions. Relationship to atherogenesis. Basic Res Cardiol, 94, 295-314.
  140. VAN BEUSEKOM, H. M., SOROP, O., VAN DEN HEUVEL, M., ONUMA, Y., DUNCKER, D. J., DANSER, A. H. & VAN DER GIESSEN, W. J. (2010) Endothelial function rather than endothelial restoration is altered in paclitaxel-as compared to bare metal-, sirolimusand tacrolimus-eluting stents. EuroIntervention, 6, 117-25.
  141. GARG, S., DUCKERS, H. J. & SERRUYS, P. W. (2010) Endothelial progenitor cell capture stents: will this technology find its niche in contemporary practice? Eur Heart J, 31, 1032-5.
  142. ROGERS, C. & EDELMAN, E. R. (1995) Endovascular stent design dictates experimental restenosis and thrombosis. Circulation, 91, 2995-3001.
  143. URAO, N., OKIGAKI, M., YAMADA, H., AADACHI, Y., MATSUNO, K., MATSUI, A., MATSUNAGA, S., TATEISHI, K., NOMURA, T., TAKAHASHI, T., TATSUMI, T. & MATSUBARA, H. (2006) Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ Res, 98, 1405-13.
  144. KIM, J. S., JANG, I. K., FAN, C., KIM, T. H., PARK, S. M., CHOI, E. Y., LEE, S. H., KO, Y. G., CHOI, D., HONG, M. K. & JANG, Y. (2009b) Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial. JACC Cardiovasc Interv, 2, 1240-7.
  145. COSTA, J. R., JR., ABIZAID, A., FERES, F., COSTA, R., SEIXAS, A. C., MAIA, F., TANAJURA, L. F., STAICO, R., SIQUEIRA, D., MEREDITH, L., BHAT, V., YAN, J., ORMISTON, J., SOUSA, A. G., FITZGERALD, P. & SOUSA, J. E. (2008) EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention, 4, 53-8.
  146. REIDY, M. A., FINGERLE, J. & LINDNER, V. (1992) Factors controlling the development of arterial lesions after injury. Circulation, 86, III43-6.
  147. ROSENFELD, M. E., TSUKADA, T., CHAIT, A., BIERMAN, E. L., GOWN, A. M. & ROSS, R. (1987) Fatty streak expansion and maturation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis, 7, 24-34.
  148. LIISTRO, F., STANKOVIC, G., DI MARIO, C., TAKAGI, T., CHIEFFO, A., MOSHIRI, S., MONTORFANO, M., CARLINO, M., BRIGUORI, C., PAGNOTTA, P., ALBIERO, R., CORVAJA, N. & COLOMBO, A. (2002) First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation, 105, 1883- 6.
  149. WEISZ, G., LEON, M. B., HOLMES, D. R., JR., KEREIAKES, D. J., POPMA, J. J., TEIRSTEIN, P. S., COHEN, S. A., WANG, H., CUTLIP, D. E. & MOSES, J. W. (2009) Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol, 53, 1488-97.
  150. MEREDITH, I. T., ORMISTON, J., WHITBOURN, R., KAY, I. P., MULLER, D., POPMA, J. J., CUTLIP, D. E. & FITZGERALD, P. J. (2007a) Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in- human study. Am J Cardiol, 100, 56M-61M.
  151. DAEMEN, J., KUKREJA, N., VAN TWISK, P. H., ONUMA, Y., DE JAEGERE, P. P., VAN DOMBURG, R. & SERRUYS, P. W. (2008) Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry. Am J Cardiol, 101, 1105-11.
  152. KUNTZ, R. E., GIBSON, C. M., NOBUYOSHI, M. & BAIM, D. S. (1993) Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy. J Am Coll Cardiol, 21, 15-25.
  153. REIDY, M. A. (1994) Growth factors and arterial smooth muscle cell proliferation. Ann N Y Acad Sci, 714, 225-30.
  154. Grundschule und Orientierungsstufe in Hannover Praktika März 2009
  155. Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation, 117, 261-95.
  156. MOLITERNO, D. J. (2005) Healing Achilles--sirolimus versus paclitaxel. N Engl J Med, 353, 724-7.
  157. LEMOS, P. A. (2007) Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis? Catheter Cardiovasc Interv, 69, 959-60.
  158. JONER, M., NAKAZAWA, G., BONSIGNORE, C., ACAMPADO, E., STEIGERWALD, K., MERL, S., VALLBRACHT, T., KOLODGIE, F. D. & VIRMANI, R. (2010) Histopathologic evaluation of nitinol self-expanding stents in an animal model of advanced atherosclerotic lesions. EuroIntervention, 5, 737-44.
  159. KEARNEY, M., PIECZEK, A., HALEY, L., LOSORDO, D. W., ANDRES, V., SCHAINFELD, R., ROSENFIELD, K. & ISNER, J. M. (1997) Histopathology of in- stent restenosis in patients with peripheral artery disease. Circulation, 95, 1998-2002. KEREIAKES, D. J., CANNON, L. A., FELDMAN, R. L., POPMA, J. J., MAGORIEN, R., WHITBOURN, R., DAUBER, I. M., RABINOWITZ, A. C., BALL, M. W., BERTOLET, B., KABOUR, A., FOSTER, M. C., WANG, J. C., UNDERWOOD, P. & DAWKINS, K. D. (2010) Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) trial. J Am Coll Cardiol, 56, 264-71.
  160. NEBEKER, J. R., VIRMANI, R., BENNETT, C. L., HOFFMAN, J. M., SAMORE, M. H., ALVAREZ, J., DAVIDSON, C. J., MCKOY, J. M., RAISCH, D. W., WHISENANT, B. K., YARNOLD, P. R., BELKNAP, S. M., WEST, D. P., GAGE, J. E., MORSE, R. E., GLIGORIC, G., DAVIDSON, L. & FELDMAN, M. D. (2006) Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol, 47, 175-81.
  161. SCOTT, N. A., CIPOLLA, G. D., ROSS, C. E., DUNN, B., MARTIN, F. H., SIMONET, L. & WILCOX, J. N. (1996) Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. Circulation, 93, 2178-87.
  162. ROY, P., BUCH, A. N., JAVAID, A., OKABE, T., RAYA, V., PINTO SLOTTOW, T. L., STEINBERG, D. H., SMITH, K., XUE, Z., GEVORKIAN, N., SATLER, L. F., KENT, K. M., SUDDATH, W. O., PICHARD, A. D., LINDSAY, J. & WAKSMAN, R. (2008) Impact of "off-label" utilization of drug-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention. Am J Cardiol, 101, 293-9.
  163. HWANG, C. W., WU, D. & EDELMAN, E. R. (2003) Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent, 5, 7-12.
  164. SCHUHLEN, H., KASTRATI, A., PACHE, J., DIRSCHINGER, J. & SCHOMIG, A. (2001) Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol, 37, 2066-73.
  165. IAKOVOU, I., SCHMIDT, T., BONIZZONI, E., GE, L., SANGIORGI, G. M., STANKOVIC, G., AIROLDI, F., CHIEFFO, A., MONTORFANO, M., CARLINO, M., MICHEV, I., CORVAJA, N., BRIGUORI, C., GERCKENS, U., GRUBE, E. & COLOMBO, A. (2005) Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA, 293, 2126-30.
  166. KOTANI, J., AWATA, M., NANTO, S., UEMATSU, M., OSHIMA, F., MINAMIGUCHI, H., MINTZ, G. S. & NAGATA, S. (2006) Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol, 47, 2108-11.
  167. KASTRATI, A., SCHOMIG, A., DIRSCHINGER, J., MEHILLI, J., VON WELSER, N., PACHE, J., SCHUHLEN, H., SCHILLING, T., SCHMITT, C. & NEUMANN, F. J. (2000) Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. Circulation, 101, 2478-83.
  168. POYEN, V., SILVESTRI, M., LABRUNIE, P. & VALEIX, B. (2003) Indications of coronary angioplasty and stenting in 2003: what is left to surgery? J Cardiovasc Surg (Torino), 44, 307-12.
  169. RAJAVASHISTH, T. B., ANDALIBI, A., TERRITO, M. C., BERLINER, J. A., NAVAB, M., FOGELMAN, A. M. & LUSIS, A. J. (1990) Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature, 344, 254-7.
  170. KU, G., THOMAS, C. E., AKESON, A. L. & JACKSON, R. L. (1992) Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J Biol Chem, 267, 14183-8.
  171. PALMAZ, J. C., BAILEY, S., MARTON, D. & SPRAGUE, E. (2002) Influence of stent design and material composition on procedure outcome. J Vasc Surg, 36, 1031-9.
  172. INDOLFI, C., AVVEDIMENTO, E. V., RAPACCIUOLO, A., DI LORENZO, E., ESPOSITO, G., STABILE, E., FELICIELLO, A., MELE, E., GIULIANO, P., CONDORELLI, G. & ET AL. (1995) Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med, 1, 541-5.
  173. GALLO, R., PADUREAN, A., JAYARAMAN, T., MARX, S., ROQUE, M., ADELMAN, S., CHESEBRO, J., FALLON, J., FUSTER, V., MARKS, A. & BADIMON, J. J. (1999) Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation, 99, 2164-70.
  174. TAMAI, H., IGAKI, K., KYO, E., KOSUGA, K., KAWASHIMA, A., MATSUI, S., KOMORI, H., TSUJI, T., MOTOHARA, S. & UEHATA, H. (2000) Initial and 6- month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation, 102, 399-404.
  175. SCHWENKE, D. C. & CAREW, T. E. (1989a) Initiation of atherosclerotic lesions in cholesterol-fed rabbits. I. Focal increases in arterial LDL concentration precede development of fatty streak lesions. Arteriosclerosis, 9, 895-907.
  176. PRATI, F., DI MARIO, C., MOUSSA, I., REIMERS, B., MALLUS, M. T., PARMA, A., LIOY, E. & COLOMBO, A. (1999) In-stent neointimal proliferation correlates with the amount of residual plaque burden outside the stent: an intravascular ultrasound study. Circulation, 99, 1011-4. QUINN, M. T., PARTHASARATHY, S. & STEINBERG, D. (1988) Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A, 85, 2805-9.
  177. KORNOWSKI, R., HONG, M. K., TIO, F. O., BRAMWELL, O., WU, H. & LEON, M. B. (1998) In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol, 31, 224-30.
  178. SAVAGE, M. P., FISCHMAN, D. L., RAKE, R., GEBHARDT, S. & GOLDBERG, S. (1996) Interprocedural interval as a predictor of stent restenosis after previous coronary angioplasty. The Palmaz-Schatz Stent Investigators. Am J Cardiol, 78, 683- 4.
  179. NORGREN, L., HIATT, W. R., DORMANDY, J. A., NEHLER, M. R., HARRIS, K. A. & FOWKES, F. G. (2007) Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg, 45 Suppl S, S5-67.
  180. SABATE, M., PIMENTEL, G., PRIETO, C., CORRAL, J. M., BANUELOS, C., ANGIOLILLO, D. J., ALFONSO, F., HERNANDEZ-ANTOLIN, R., ESCANED, J., FANTIDIS, P., FERNANDEZ, C., FERNANDEZ-ORTIZ, A., MORENO, R. & MACAYA, C. (2004) Intracoronary brachytherapy after stenting de novo lesions in diabetic patients: results of a randomized intravascular ultrasound study. J Am Coll Cardiol, 44, 520-7.
  181. KASTRATI, A., MEHILLI, J., DIRSCHINGER, J., DOTZER, F., SCHUHLEN, H., NEUMANN, F. J., FLECKENSTEIN, M., PFAFFEROTT, C., SEYFARTH, M. & SCHOMIG, A. (2001) Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation, 103, 2816-21.
  182. LEON, M. B. & WONG, S. C. (1994) Intracoronary stents. A breakthrough technology or just another small step? Circulation, 89, 1323-7.
  183. SIGWART, U., PUEL, J., MIRKOVITCH, V., JOFFRE, F. & KAPPENBERGER, L. (1987) Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med, 316, 701-6.
  184. TAKEBAYASHI, H., KOBAYASHI, Y., MINTZ, G. S., CARLIER, S. G., FUJII, K., YASUDA, T., MOUSSA, I., MEHRAN, R., DANGAS, G. D., COLLINS, M. B., KREPS, E., LANSKY, A. J., STONE, G. W., LEON, M. B. & MOSES, J. W. (2005) Intravascular ultrasound assessment of lesions with target vessel failure after sirolimus-eluting stent implantation. Am J Cardiol, 95, 498-502.
  185. HOFFMANN, R., MINTZ, G. S., MEHRAN, R., PICHARD, A. D., KENT, K. M., SATLER, L. F., POPMA, J. J., WU, H. & LEON, M. B. (1998) Intravascular ultrasound predictors of angiographic restenosis in lesions treated with Palmaz-Schatz stents. J Am Coll Cardiol, 31, 43-9.
  186. INDOLFI, C., AVVEDIMENTO, E. V., RAPACCIUOLO, A., ESPOSITO, G., DI LORENZO, E., LECCIA, A., PISANI, A., CHIEFFO, A., COPPOLA, A. & CHIARIELLO, M. (1997) In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase. Basic Res Cardiol, 92, 378-84.
  187. & OH, D. J. (2009) Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with Paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Circ J, 73, 2229-35.
  188. PFISTERER, M., BRUNNER-LA ROCCA, H. P., BUSER, P. T., RICKENBACHER, P., HUNZIKER, P., MUELLER, C., JEGER, R., BADER, F., OSSWALD, S. & KAISER, C. (2006) Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare- metal stents. J Am Coll Cardiol, 48, 2584-91.
  189. MAURI, L., ORAV, E. J. & KUNTZ, R. E. (2005b) Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation, 111, 3435-42.
  190. MCEVER, R. P. (1992) Leukocyte-endothelial cell interactions. Curr Opin Cell Biol, 4, 840- 9.
  191. NIEVELSTEIN, P. F., FOGELMAN, A. M., MOTTINO, G. & FRANK, J. S. (1991) Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of low density lipoprotein. A deep-etch and immunolocalization study of ultrarapidly frozen tissue. Arterioscler Thromb, 11, 1795-805.
  192. VIRMANI, R., GUAGLIUMI, G., FARB, A., MUSUMECI, G., GRIECO, N., MOTTA, T., MIHALCSIK, L., TESPILI, M., VALSECCHI, O. & KOLODGIE, F. D. (2004) Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus- eluting stent: should we be cautious? Circulation, 109, 701-5.
  193. GYONGYOSI, M., YANG, P., KHORSAND, A. & GLOGAR, D. (2000) Longitudinal straightening effect of stents is an additional predictor for major adverse cardiac events. Austrian Wiktor Stent Study Group and European Paragon Stent Investigators. J Am Coll Cardiol, 35, 1580-9.
  194. SCHLAGER, O., DICK, P., SABETI, S., AMIGHI, J., MLEKUSCH, W., MINAR, E. & SCHILLINGER, M. (2005) Long-segment SFA stenting--the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther, 12, 676-84. SCHOFER, J., SCHLUTER, M., GERSHLICK, A. H., WIJNS, W., GARCIA, E., SCHAMPAERT, E. & BREITHARDT, G. (2003) Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet, 362, 1093-9.
  195. NISHIO, S., KOSUGA, K. & OKADA, M. (2010) Long-term (>10 years) clinical outcomes of first-in-men biodegradable poly-l-lactic acid coronary stens. paper presented at: EuroPCR; May 25-28, 2010; Paris, France.
  196. MORICE, M. C., SERRUYS, P. W., BARRAGAN, P., BODE, C., VAN ES, G. A., STOLL, H. P., SNEAD, D., MAURI, L., CUTLIP, D. E. & SOUSA, E. (2007) Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol, 50, 1299-304.
  197. TAYLOR, A. J., GORMAN, P. D., FARB, A., HOOPES, T. G. & VIRMANI, R. (1999) Long-term coronary vascular response to (32)P beta-particle-emitting stents in a canine model. Circulation, 100, 2366-72.
  198. MISHKEL, G. J., MOORE, A. L., MARKWELL, S., SHELTON, M. C. & SHELTON, M. E. (2007) Long-term outcomes after management of restenosis or thrombosis of drug- eluting stents. J Am Coll Cardiol, 49, 181-4.
  199. LAGERQVIST, B., JAMES, S. K., STENESTRAND, U., LINDBACK, J., NILSSON, T. & WALLENTIN, L. (2007) Long-term outcomes with drug-eluting stents versus bare- metal stents in Sweden. N Engl J Med, 356, 1009-19.
  200. KIM, H. S., LEE, J. H., LEE, S. W., KIM, Y. H., PARK, J. H., CHOI, S. W., JEONG, J. O., SEONG, I. W., RHEE, K. S., KO, J. K., JO, S. H. & CHOI, Y. J. (2009a) Long-term safety and efficacy of sirolimus-vs. paclitaxel-eluting stent implantation for acute ST- elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol.
  201. SHINKE, T., GEVA, S., PENDYALA, L., JABARA, R., LI, J., CHEN, J. P., VENEGONI, A., COLLEY, K., KLEIN, R., CHRONOS, N., ROBINSON, K. & HOU, D. (2009) Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries. Int J Cardiol, 135, 93-101.
  202. SUTTON, J. M., ELLIS, S. G., ROUBIN, G. S., PINKERTON, C. A., KING, S. B., 3RD, RAIZNER, A. E., HOLMES, D. R., KEREIAKES, D. J. & TOPOL, E. J. (1994) Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation, 89, 1126-37.
  203. HABERLAND, M. E., FONG, D. & CHENG, L. (1988) Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science, 241, 215-8. HAMILOS, M. I., OSTOJIC, M., BELESLIN, B., SAGIC, D., MANGOVSKI, L., STOJKOVIC, S., NEDELJKOVIC, M., ORLIC, D., MILOSAVLJEVIC, B., TOPIC, D., KARANOVIC, N. & WIJNS, W. (2008) Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J Am Coll Cardiol, 51, 2123-9.
  204. VAN DER GIESSEN, W. J., LINCOFF, A. M., SCHWARTZ, R. S., VAN BEUSEKOM, H. M., SERRUYS, P. W., HOLMES, D. R., JR., ELLIS, S. G. & TOPOL, E. J. (1996) Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation, 94, 1690-7.
  205. DEMER, L. L., WORTHAM, C. M., DIRKSEN, E. R. & SANDERSON, M. J. (1993) Mechanical stimulation induces intercellular calcium signaling in bovine aortic endothelial cells. Am J Physiol, 264, H2094-102.
  206. DEMER LL, W. K., BOSTRÖM K (1994) Mechanism of Calcification in Atherosclerosis. Trends Cardiovasc Med, 4 (1), 45-49.
  207. INOUE, T., SATA, M., HIKICHI, Y., SOHMA, R., FUKUDA, D., UCHIDA, T., SHIMIZU, M., KOMODA, H. & NODE, K. (2007) Mobilization of CD34-positive bone marrow- derived cells after coronary stent implantation: impact on restenosis. Circulation, 115, 553-61.
  208. COSTA, M. A. & SIMON, D. I. (2005) Molecular basis of restenosis and drug-eluting stents. Circulation, 111, 2257-73.
  209. INDOLFI, C., MONGIARDO, A., CURCIO, A. & TORELLA, D. (2003) Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents. Trends Cardiovasc Med, 13, 142-8.
  210. KRAGEL, A. H., REDDY, S. G., WITTES, J. T. & ROBERTS, W. C. (1989) Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. Circulation, 80, 1747-56.
  211. Famulatur am Universitätsklinikum Tübingen in der Hals-, Nasen-, Ohrenklinik Sonstige Erfahrungen 2007 Sechswöchiger Aufenthalt in Kenia/Tansania 2004 Regattaorganisation in Kiel 2003 Schülervertreterin des Kaiser-Wilhelm-und Ratsgymnasiums August 1999
  212. PEREZ, G., RODRIGUEZ-GRANILLO, A. M., MIERES, J., LLAURADO, C., RUBILAR, B., RISAU, G., FERNANDEZ-PEREIRA, C. & RODRIGUEZ, A. E. (2009) New coating stent design for patients with high-risk coronary lesions for thrombotic events: early and long-term results of the camouflage registry. J Invasive Cardiol, 21, 378-82.
  213. SOUSA, J. E., SERRUYS, P. W. & COSTA, M. A. (2003c) New frontiers in cardiology: drug-eluting stents: Part I. Circulation, 107, 2274-9.
  214. KOSTER, R., VIELUF, D., KIEHN, M., SOMMERAUER, M., KAHLER, J., BALDUS, S., MEINERTZ, T. & HAMM, C. W. (2000) Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet, 356, 1895-7.
  215. THIERRY, B., MERHI, Y., BILODEAU, L., TREPANIER, C. & TABRIZIAN, M. (2002) Nitinol versus stainless steel stents: acute thrombogenicity study in an ex vivo porcine model. Biomaterials, 23, 2997-3005.
  216. JABARA, R., CHRONOS, N. & ROBINSON, K. (2008) Novel bioabsorbable salicylate- based polymer as a drug-eluting stent coating. Catheter Cardiovasc Interv, 72, 186-94.
  217. PINTO SLOTTOW, T. L., STEINBERG, D. H., ROY, P. K., BUCH, A. N., OKABE, T., XUE, Z., KANESHIGE, K., TORGUSON, R., LINDSAY, J., PICHARD, A. D., SATLER, L. F., SUDDATH, W. O., KENT, K. M. & WAKSMAN, R. (2008) Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol, 102, 298-303.
  218. STONE, G. W., ELLIS, S. G., COLOMBO, A., DAWKINS, K. D., GRUBE, E., CUTLIP, D. E., FRIEDMAN, M., BAIM, D. S. & KOGLIN, J. (2007a) Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation, 115, 2842-7.
  219. VAN HOUT, B. A., SERRUYS, P. W., LEMOS, P. A., VAN DEN BRAND, M. J., VAN ES, G. A., LINDEBOOM, W. K. & MORICE, M. C. (2005) One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: an analysis from the RAVEL trial. Heart, 91, 507-12. VAN WERKUM, J. W., HEESTERMANS, A. A., ZOMER, A. C., KELDER, J. C., SUTTORP, M. J., RENSING, B. J., KOOLEN, J. J., BRUEREN, B. R., DAMBRINK, J. H., HAUTVAST, R. W., VERHEUGT, F. W. & TEN BERG, J. M. (2009) Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol, 53, 1399-409.
  220. KIM, J. S., JANG, I. K., KIM, T. H., TAKANO, M., KUME, T., HUR, N. W., KO, Y. G., CHOI, D., HONG, M. K. & JANG, Y. (2009c) Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents. Heart, 95, 1907-12.
  221. LEHR, H. A., HUBNER, C., NOLTE, D., FINCKH, B., BEISIEGEL, U., KOHLSCHUTTER, A. & MESSMER, K. (1991) Oxidatively modified human low- density lipoprotein stimulates leukocyte adherence to the microvascular endothelium in vivo. Res Exp Med (Berl), 191, 85-90.
  222. MURUGESAN, G., CHISOLM, G. M. & FOX, P. L. (1993) Oxidized low density lipoprotein inhibits the migration of aortic endothelial cells in vitro. J Cell Biol, 120, 1011-9. NAKAMURA, M., YAMASHITA, T., YAJIMA, J., OIKAWA, Y., OGASAWARA, K., KIRIGAYA, H., NAGASHIMA, K., SAWADA, H. & AIZAWA, T. (2009) Long- term safety and efficacy of sirolimus-eluting stents in Japanese patients: a single- center cohort study. J Invasive Cardiol, 21, 526-31.
  223. GALLE, J., BASSENGE, E. & BUSSE, R. (1990) Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res, 66, 1287-93.
  224. WITZTUM, J. L. & BERLINER, J. A. (1998) Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol, 9, 441-8.
  225. UNVERDORBEN, M., VALLBRACHT, C., CREMERS, B., HEUER, H., HENGSTENBERG, C., MAIKOWSKI, C., WERNER, G. S., ANTONI, D., KLEBER, F. X., BOCKSCH, W., LESCHKE, M., ACKERMANN, H., BOXBERGER, M., SPECK, U., DEGENHARDT, R. & SCHELLER, B. (2009) Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation, 119, 2986-94.
  226. SILBER, S. (2003) Paclitaxel-eluting stents: are they all equal? An analysis of six randomized controlled trials in de novo lesions of 3,319 patients. J Interv Cardiol, 16, 485-90.
  227. ROWINSKY, E. K. & DONEHOWER, R. C. (1995) Paclitaxel (taxol). N Engl J Med, 332, 1004-14.
  228. PENDYALA, L., JABARA, R., ROBINSON, K. & CHRONOS, N. (2009) Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. J Interv Cardiol, 22, 37-48.
  229. SCHILLINGER, M. & MINAR, E. (2009) Past, present and future of femoropopliteal stenting. J Endovasc Ther, 16 Suppl 1, I147-52.
  230. JONER, M., FINN, A. V., FARB, A., MONT, E. K., KOLODGIE, F. D., LADICH, E., KUTYS, R., SKORIJA, K., GOLD, H. K. & VIRMANI, R. (2006) Pathology of drug- eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol, 48, 193-202.
  231. SCHWARTZ, R. S. & HENRY, T. D. (2002) Pathophysiology of coronary artery restenosis. Rev Cardiovasc Med, 3 Suppl 5, S4-9.
  232. HOFFMANN, R., MINTZ, G. S., DUSSAILLANT, G. R., POPMA, J. J., PICHARD, A. D., SATLER, L. F., KENT, K. M., GRIFFIN, J. & LEON, M. B. (1996) Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation, 94, 1247-54.
  233. SERRUYS, P. W., KAY, I. P., DISCO, C., DESHPANDE, N. V. & DE FEYTER, P. J. (1999) Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coronaries. J Am Coll Cardiol, 34, 1067-74.
  234. MUDRA, H., BODE, C., GRUBE, E., DE HAAN, F., LEVENSON, B., SCHULER, G. & SILBER, S. (2004) [Position paper on the use of drug eluting stents in coronary heart disease]. Z Kardiol, 93, 416-22.
  235. GOLDBERG, S. L., LOUSSARARIAN, A., DE GREGORIO, J., DI MARIO, C., ALBIERO, R. & COLOMBO, A. (2001) Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol, 37, 1019-25.
  236. MIGLIORINI, A., SHEHU, M., CARRABBA, N., GIURLANI, L., VALENTI, R., BUONAMICI, P., DOVELLINI, E. V., PARODI, G. & ANTONIUCCI, D. (2005) Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis. Am J Cardiol, 96, 1110-2.
  237. CHENEAU, E., LEBORGNE, L., MINTZ, G. S., KOTANI, J., PICHARD, A. D., SATLER, L. F., CANOS, D., CASTAGNA, M., WEISSMAN, N. J. & WAKSMAN, R. (2003) Predictors of subacute stent thrombosis: results of a systematic intravascular ultrasound study. Circulation, 108, 43-7.
  238. COLOMBO, A., ORLIC, D., STANKOVIC, G., CORVAJA, N., SPANOS, V., MONTORFANO, M., LIISTRO, F., CARLINO, M., AIROLDI, F., CHIEFFO, A. & DI MARIO, C. (2003) Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation, 107, 2178-80.
  239. SCHEINERT, D., SCHEINERT, S., SAX, J., PIORKOWSKI, C., BRAUNLICH, S., ULRICH, M., BIAMINO, G. & SCHMIDT, A. (2005) Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol, 45, 312-5.
  240. SPERTUS, J. A., KETTELKAMP, R., VANCE, C., DECKER, C., JONES, P. G., RUMSFELD, J. S., MESSENGER, J. C., KHANAL, S., PETERSON, E. D., BACH, R. G., KRUMHOLZ, H. M. & COHEN, D. J. (2006) Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation, 113, 2803-9. SSYLVIASTUDYINVESTIGATORS (2004) Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke, 35, 1388-92.
  241. WERNER, G. S., KRACK, A., SCHWARZ, G., PROCHNAU, D., BETGE, S. & FIGULLA, H. R. (2004) Prevention of lesion recurrence in chronic total coronary occlusions by paclitaxel-eluting stents. J Am Coll Cardiol, 44, 2301-6.
  242. SCHELLER, B., SPECK, U. & BOHM, M. (2007) Prevention of restenosis: is angioplasty the answer? Heart, 93, 539-41.
  243. SABETI, S., SCHILLINGER, M., AMIGHI, J., SHERIF, C., MLEKUSCH, W., AHMADI, R. & MINAR, E. (2004) Primary patency of femoropopliteal arteries treated with nitinol versus stainless steel self-expanding stents: propensity score-adjusted analysis. Radiology, 232, 516-21.
  244. KASTRATI, A., SCHOMIG, A., ELEZI, S., DIRSCHINGER, J., MEHILLI, J., SCHUHLEN, H., BLASINI, R. & NEUMANN, F. J. (1999) Prognostic value of the modified american college of Cardiology/American heart association stenosis morphology classification for long-term angiographic and clinical outcome after coronary stent placement. Circulation, 100, 1285-90.
  245. VAINA, S. & SERRUYS, P. W. (2006) Progressive stent technologies: new approaches for the treatment of cardiovascular diseases. Expert Opin Drug Deliv, 3, 783-97.
  246. WAKSMAN, R. (2007) Promise and challenges of bioabsorbable stents. Catheter Cardiovasc Interv, 70, 407-14.
  247. HOFF, H. F., HEIDEMAN, C. L., GAUBATZ, J. W., GOTTO, A. M., JR., ERICKSON, E. E. & JACKSON, R. L. (1977b) Quantification of apolipoprotein B in grossly normal human aorta. Circ Res, 40, 56-64.
  248. COLOMBO, A., MOSES, J. W., MORICE, M. C., LUDWIG, J., HOLMES, D. R., JR., SPANOS, V., LOUVARD, Y., DESMEDT, B., DI MARIO, C. & LEON, M. B. (2004) Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation, 109, 1244-9.
  249. MEHILLI, J., KASTRATI, A., WESSELY, R., DIBRA, A., HAUSLEITER, J., JASCHKE, B., DIRSCHINGER, J. & SCHOMIG, A. (2006) Randomized trial of a nonpolymer- based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation, 113, 273-9.
  250. WESSELY, R., KASTRATI, A., MEHILLI, J., DIBRA, A., PACHE, J. & SCHOMIG, A. (2007) Randomized trial of rapamycin-and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J, 28, 2720-5.
  251. STEFFEL, J., LATINI, R. A., AKHMEDOV, A., ZIMMERMANN, D., ZIMMERLING, P., LUSCHER, T. F. & TANNER, F. C. (2005) Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation, 112, 2002-11.
  252. BUTZAL, M., LOGES, S., SCHWEIZER, M., FISCHER, U., GEHLING, U. M., HOSSFELD, D. K. & FIEDLER, W. (2004) Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro. Exp Cell Res, 300, 65- 71.
  253. SAUNDERS, R. N., METCALFE, M. S. & NICHOLSON, M. L. (2001) Rapamycin in transplantation: a review of the evidence. Kidney Int, 59, 3-16.
  254. TARNOK, A., MAHNKE, A., MULLER, M. & ZOTZ, R. J. (1999) Rapid in vitro biocompatibility assay of endovascular stents by flow cytometry using platelet activation and platelet-leukocyte aggregation. Cytometry, 38, 30-9.
  255. J. (2001) Recent Developments in Coated Stents. Curr Interv Cardiol Rep, 3, 28-36.
  256. MAURI, L., ORAV, E. J., O'MALLEY, A. J., MOSES, J. W., LEON, M. B., HOLMES, D. R., JR., TEIRSTEIN, P. S., SCHOFER, J., BREITHARDT, G., CUTLIP, D. E., KEREIAKES, D. J., SHI, C., FIRTH, B. G., DONOHOE, D. J. & KUNTZ, R. E. (2005c) Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation, 111, 321-7.
  257. WINSLOW, R. D., SHARMA, S. K. & KIM, M. C. (2005) Restenosis and drug-eluting stents. Mt Sinai J Med, 72, 81-9.
  258. SCHWARTZ, R. S., HUBER, K. C., MURPHY, J. G., EDWARDS, W. D., CAMRUD, A. R., VLIETSTRA, R. E. & HOLMES, D. R. (1992) Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol, 19, 267-74.
  259. WITZTUM, J. L. & STEINBERG, D. (1991) Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest, 88, 1785-92.
  260. HARA, H., NAKAMURA, M., PALMAZ, J. C. & SCHWARTZ, R. S. (2006) Role of stent design and coatings on restenosis and thrombosis. Adv Drug Deliv Rev, 58, 377-86.
  261. & TU, J. V. (2009) Safety and effectiveness of drug-eluting and bare-metal stents for patients with off-and on-label indications. J Am Coll Cardiol, 53, 1773-82.
  262. STONE, G. W., MOSES, J. W., ELLIS, S. G., SCHOFER, J., DAWKINS, K. D., MORICE, M. C., COLOMBO, A., SCHAMPAERT, E., GRUBE, E., KIRTANE, A. J., CUTLIP, D. E., FAHY, M., POCOCK, S. J., MEHRAN, R. & LEON, M. B. (2007b) Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N Engl J Med, 356, 998- 1008.
  263. OTSUKA, Y., CHRONOS, N. A., APKARIAN, R. P. & ROBINSON, K. A. (2007) Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J Invasive Cardiol, 19, 71-6.
  264. SCHULER, W., SEDRANI, R., COTTENS, S., HABERLIN, B., SCHULZ, M., SCHUURMAN, H. J., ZENKE, G., ZERWES, H. G. & SCHREIER, M. H. (1997) SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation, 64, 36-42.
  265. STOECKEL, D., PELTON, A. & DUERIG, T. (2004) Self-expanding nitinol stents: material and design considerations. Eur Radiol, 14, 292-301.
  266. LEMOS, P. A., SAIA, F., HOFMA, S. H., DAEMEN, J., ONG, A. T., ARAMPATZIS, C. A., HOYE, A., MCFADDEN, E., SIANOS, G., SMITS, P. C., VAN DER GIESSEN, W. J., DE FEYTER, P., VAN DOMBURG, R. T. & SERRUYS, P. W. (2004b) Short-and long-term clinical benefit of sirolimus-eluting stents compared to conventional bare stents for patients with acute myocardial infarction. J Am Coll Cardiol, 43, 704-8.
  267. VALGIMIGLI, M., VAN MIEGHEM, C. A., ONG, A. T., AOKI, J., GRANILLO, G. A., MCFADDEN, E. P., KAPPETEIN, A. P., DE FEYTER, P. J., SMITS, P. C., REGAR, E., VAN DER GIESSEN, W. J., SIANOS, G., DE JAEGERE, P., VAN DOMBURG, R. T. & SERRUYS, P. W. (2005b) Short-and long-term clinical outcome after drug- eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation, 111, 1383-9.
  268. SCHELLER, B., KUHLER, M., CREMERS, B., MAHNKOPF, D., BOHM, M. & BOXBERGER, M. (2008b) Short-and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol, 97, 118-23.
  269. MORI, S., YASUDA, S., KATAOKA, Y., MORII, I., KAWAMURA, A. & MIYAZAKI, S. (2009) Significant association of coronary artery calcification in stent delivery route with restenosis after sirolimus-eluting stent implantation. Circ J, 73, 1856-63.
  270. HOYE, A., TANABE, K., LEMOS, P. A., AOKI, J., SAIA, F., ARAMPATZIS, C., DEGERTEKIN, M., HOFMA, S. H., SIANOS, G., MCFADDEN, E., VAN DER GIESSEN, W. J., SMITS, P. C., DE FEYTER, P. J., VAN DOMBURG, R. T. & SERRUYS, P. W. (2004) Significant reduction in restenosis after the use of sirolimus- eluting stents in the treatment of chronic total occlusions. J Am Coll Cardiol, 43, 1954-8.
  271. WESSELY, R., SCHOMIG, A. & KASTRATI, A. (2006) Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. J Am Coll Cardiol, 47, 708- 14.
  272. WINDECKER, S., REMONDINO, A., EBERLI, F. R., JUNI, P., RABER, L., WENAWESER, P., TOGNI, M., BILLINGER, M., TULLER, D., SEILER, C., ROFFI, M., CORTI, R., SUTSCH, G., MAIER, W., LUSCHER, T., HESS, O. M., EGGER, M. & MEIER, B. (2005) Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med, 353, 653-62.
  273. DEGERTEKIN, M., REGAR, E., TANABE, K., SMITS, P. C., VAN DER GIESSEN, W. J., CARLIER, S. G., DE FEYTER, P., VOS, J., FOLEY, D. P., LIGTHART, J. M., POPMA, J. J. & SERRUYS, P. W. (2003) Sirolimus-eluting stent for treatment of complex in-stent restenosis: the first clinical experience. J Am Coll Cardiol, 41, 184-9. DEGERTEKIN, M., SERRUYS, P. W., FOLEY, D. P., TANABE, K., REGAR, E., VOS, J., SMITS, P. C., VAN DER GIESSEN, W. J., VAN DEN BRAND, M., DE FEYTER, P. & POPMA, J. J. (2002) Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up. Circulation, 106, 1610-3.
  274. TOGNI, M., WINDECKER, S., COCCHIA, R., WENAWESER, P., COOK, S., BILLINGER, M., MEIER, B. & HESS, O. M. (2005) Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J Am Coll Cardiol, 46, 231-6.
  275. CARROZZA, J. P., JR. (2004) Sirolimus-eluting stents: does a great stent still need a good interventionalist? J Am Coll Cardiol, 43, 1116-7.
  276. MOSES, J. W., LEON, M. B., POPMA, J. J., FITZGERALD, P. J., HOLMES, D. R., O'SHAUGHNESSY, C., CAPUTO, R. P., KEREIAKES, D. J., WILLIAMS, D. O., TEIRSTEIN, P. S., JAEGER, J. L. & KUNTZ, R. E. (2003) Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 349, 1315-23.
  277. KASTRATI, A., DIBRA, A., EBERLE, S., MEHILLI, J., SUAREZ DE LEZO, J., GOY, J. J., ULM, K. & SCHOMIG, A. (2005a) Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA, 294, 819-25.
  278. SONG, Y. B., HAHN, J. Y., CHOI, S. H., CHOI, J. H., LEE, S. H., JEONG, M. H., KIM, H. S., SEONG, I. W., YANG, J. Y., RHA, S. W., JANG, Y., YOON, J. H., TAHK, S. J., SEUNG, K. B., PARK, S. J. & GWON, H. C. (2010) Sirolimus-versus paclitaxel- eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry. J Am Coll Cardiol, 55, 1743-50.
  279. RÄBER, L. (2009) SIRTAX-LATE: five-year clinical and angiographic follow-up from a prospective randomized trial of sirolimus-eluting and paclitaxel-eluting stents. Paper presented at: Transcatheter Cardiovascular Therapeutica; September 22, 2009; San Francisco.
  280. WILLERSON, J. T., GOLINO, P., EIDT, J., CAMPBELL, W. B. & BUJA, L. M. (1989) Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation, 80, 198-205.
  281. REZVAN, A., ALLEN, F. D. & LELKES, P. I. (2004) Steady unidirectional laminar flow inhibits monolayer formation by human and rat microvascular endothelial cells. Endothelium, 11, 11-6.
  282. WINDECKER, S., BILLINGER, M. & HESS, O. M. (2006) Stent coating with titanium- nitride-oxide for prevention of restenosis. EuroIntervention, 2, 146-8.
  283. MCLEAN, D. R. & EIGER, N. L. (2002) Stent design: implications for restenosis. Rev Cardiovasc Med, 3 Suppl 5, S16-22.
  284. KONIG, A., SCHIELE, T. M., RIEBER, J., THEISEN, K., MUDRA, H. & KLAUSS, V. (2002) Stent design-related coronary artery remodeling and patterns of neointima formation following self-expanding and balloon-expandable stent implantation. Catheter Cardiovasc Interv, 56, 478-86.
  285. REGAR, E., SIANOS, G. & SERRUYS, P. W. (2001) Stent development and local drug delivery. Br Med Bull, 59, 227-48.
  286. KOBAYASHI, Y., DE GREGORIO, J., KOBAYASHI, N., AKIYAMA, T., REIMERS, B., FINCI, L., DI MARIO, C. & COLOMBO, A. (1999) Stented segment length as an independent predictor of restenosis. J Am Coll Cardiol, 34, 651-9.
  287. BROTT, T. G., HOBSON, R. W., 2ND, HOWARD, G., ROUBIN, G. S., CLARK, W. M., BROOKS, W., MACKEY, A., HILL, M. D., LEIMGRUBER, P. P., SHEFFET, A. J., HOWARD, V. J., MOORE, W. S., VOEKS, J. H., HOPKINS, L. N., CUTLIP, D. E., COHEN, D. J., POPMA, J. J., FERGUSON, R. D., COHEN, S. N., BLACKSHEAR, J. L., SILVER, F. L., MOHR, J. P., LAL, B. K. & MESCHIA, J. F. (2010) Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med, 363, 11- 23.
  288. PARK, D. W., YUN, S. C., LEE, S. W., KIM, Y. H., LEE, C. W., HONG, M. K., CHEONG, S. S., KIM, J. J., PARK, S. W. & PARK, S. J. (2008) Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents. JACC Cardiovasc Interv, 1, 494-503.
  289. MAURI, L., HSIEH, W. H., MASSARO, J. M., HO, K. K., D'AGOSTINO, R. & CUTLIP, D. E. (2007) Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med, 356, 1020-9.
  290. LATRON, Y., CHAUTAN, M., ANFOSSO, F., ALESSI, M. C., NALBONE, G., LAFONT, H. & JUHAN-VAGUE, I. (1991) Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb, 11, 1821-9.
  291. GERRITY, R. G. & SCHWARTZ, C. J. (1977) Structural correlates of arterial endothelial permeability in the Evans blue model. Prog Biochem Pharmacol, 13, 134-7.
  292. YAMAZOE, N., HASHIMOTO, N., KIKUCHI, H., KANG, Y., NAKATANI, H. & HAZAMA, F. (1990) Study of the elastic skeleton of intracranial arteries in animal and human vessels by scanning electron microscopy. Stroke, 21, 765-70.
  293. SHETH, S., LITVACK, F., DEV, V., FISHBEIN, M. C., FORRESTER, J. S. & EIGLER, N. (1996) Subacute thrombosis and vascular injury resulting from slotted-tube nitinol and stainless steel stents in a rabbit carotid artery model. Circulation, 94, 1733-40.
  294. KRUTH, H. S. (1985) Subendothelial accumulation of unesterified cholesterol. An early event in atherosclerotic lesion development. Atherosclerosis, 57, 337-41.
  295. SCHILLINGER, M., SABETI, S., DICK, P., AMIGHI, J., MLEKUSCH, W., SCHLAGER, O., LOEWE, C., CEJNA, M., LAMMER, J. & MINAR, E. (2007) Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation, 115, 2745-9.
  296. ONG, A. T. & SERRUYS, P. W. (2005) Technology Insight: an overview of research in drug-eluting stents. Nat Clin Pract Cardiovasc Med, 2, 647-58.
  297. SCHAMPAERT, E., COHEN, E. A., SCHLUTER, M., REEVES, F., TRABOULSI, M., TITLE, L. M., KUNTZ, R. E. & POPMA, J. J. (2004) The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol, 43, 1110-5.
  298. CASTAGNA, M. T., MINTZ, G. S., LEIBOFF, B. O., AHMED, J. M., MEHRAN, R., SATLER, L. F., KENT, K. M., PICHARD, A. D. & WEISSMAN, N. J. (2001) The contribution of "mechanical" problems to in-stent restenosis: An intravascular ultrasonographic analysis of 1090 consecutive in-stent restenosis lesions. Am Heart J, 142, 970-4.
  299. KITTLESON, M. M., NEEDHAM, D. M., KIM, S. J., RAVINDRAN, B. K., SOLOMON, S. S. & GUALLAR, E. (2005) The efficacy of sirolimus-and paclitaxel-eluting stents: a meta-analysis of randomized controlled trials. Can J Cardiol, 21, 581-7.
  300. ONUMA, Y., KUKREJA, N., PIAZZA, N., EINDHOVEN, J., GIRASIS, C., SCHENKEVELD, L., VAN DOMBURG, R. & SERRUYS, P. W. (2009) The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry. J Am Coll Cardiol, 54, 269-76.
  301. JONER, M. & BYRNE, R. A. (2010) The importance of preclinical research in contemporary interventional cardiology. EuroIntervention, 6, 19-23.
  302. MEREDITH, I. T., WORTHLEY, S., WHITBOURN, R., WALTERS, D., POPMA, J., CUTLIP, D. & FITZGERALD, P. (2007b) The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in- man trial. EuroIntervention, 3, 50-3.
  303. HEDIN, M. (1997) The origin of the word Stent. Acta Radiol, 38, 937-9.
  304. WITZTUM, J. L. (1994) The oxidation hypothesis of atherosclerosis. Lancet, 344, 793-5.
  305. ROSS, R. (1986) The pathogenesis of atherosclerosis--an update. N Engl J Med, 314, 488- 500.
  306. FUSTER, V., BADIMON, L., BADIMON, J. J. & CHESEBRO, J. H. (1992) The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med, 326, 242-50.
  307. SMITH, E. B. (1974) The relationship between plasma and tissue lipids in human atherosclerosis. Adv Lipid Res, 12, 1-49.
  308. WILCOX, J. N., WAKSMAN, R., KING, S. B. & SCOTT, N. A. (1996) The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys, 36, 789-96.
  309. MCKEAGE, K., MURDOCH, D. & GOA, K. L. (2003) The sirolimus-eluting stent: a review of its use in the treatment of coronary artery disease. Am J Cardiovasc Drugs, 3, 211- 30.
  310. ONG, A. T., SERRUYS, P. W., AOKI, J., HOYE, A., VAN MIEGHEM, C. A., RODRIGUEZ-GRANILLO, G. A., VALGIMIGLI, M., SONNENSCHEIN, K., REGAR, E., VAN DER ENT, M., DE JAEGERE, P. P., MCFADDEN, E. P., SIANOS, G., VAN DER GIESSEN, W. J., DE FEYTER, P. J. & VAN DOMBURG, R. T. (2005b) The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus- Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol, 45, 1135-41.
  311. ONG, A. T., HOYE, A., AOKI, J., VAN MIEGHEM, C. A., RODRIGUEZ GRANILLO, G. A., SONNENSCHEIN, K., REGAR, E., MCFADDEN, E. P., SIANOS, G., VAN DER GIESSEN, W. J., DE JAEGERE, P. P., DE FEYTER, P., VAN DOMBURG, R. T. & SERRUYS, P. W. (2005a) Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol, 45, 947-53.
  312. DE JONG, W. H., EELCO BERGSMA, J., ROBINSON, J. E. & BOS, R. R. (2005) Tissue response to partially in vitro predegraded poly-L-lactide implants. Biomaterials, 26, 1781-91.
  313. CORNHILL, J. F., HERDERICK, E. E. & STARY, H. C. (1990) Topography of human aortic sudanophilic lesions. Monogr Atheroscler, 15, 13-9.
  314. REID, V. C. & MITCHINSON, M. J. (1993) Toxicity of oxidised low density lipoprotein towards mouse peritoneal macrophages in vitro. Atherosclerosis, 98, 17-24.
  315. SCHELLER, B., HEHRLEIN, C., BOCKSCH, W., RUTSCH, W., HAGHI, D., DIETZ, U., BOHM, M. & SPECK, U. (2006) Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 355, 2113-24.
  316. ORLIC, D., BONIZZONI, E., STANKOVIC, G., AIROLDI, F., CHIEFFO, A., CORVAJA, N., SANGIORGI, G., FERRARO, M., BRIGUORI, C., MONTORFANO, M., CARLINO, M. & COLOMBO, A. (2004) Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol, 43, 1154-60.
  317. TAKAGI, T., AKASAKA, T., YAMAMURO, A., HONDA, Y., HOZUMI, T., MORIOKA, S. & YOSHIDA, K. (2000) Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol, 36, 1529-35.
  318. KLUGHERZ, B. D., LLANOS, G., LIEUALLEN, W., KOPIA, G. A., PAPANDREOU, G., NARAYAN, P., SASSEEN, B., ADELMAN, S. J., FALOTICO, R. & WILENSKY, R. L. (2002) Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. Coron Artery Dis, 13, 183-8.
  319. SCHELLER, B., HEHRLEIN, C., BOCKSCH, W., RUTSCH, W., HAGHI, D., DIETZ, U., BOHM, M. & SPECK, U. (2008a) Two year follow-up after treatment of coronary in- stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol, 97, 773- 81.
  320. WEISZ, G., LEON, M. B., HOLMES, D. R., JR., KEREIAKES, D. J., CLARK, M. R., COHEN, B. M., ELLIS, S. G., COLEMAN, P., HILL, C., SHI, C., CUTLIP, D. E., KUNTZ, R. E. & MOSES, J. W. (2006) Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J Am Coll Cardiol, 47, 1350-5.
  321. LEMOS, P. A., SERRUYS, P. W., VAN DOMBURG, R. T., SAIA, F., ARAMPATZIS, C. A., HOYE, A., DEGERTEKIN, M., TANABE, K., DAEMEN, J., LIU, T. K., MCFADDEN, E., SIANOS, G., HOFMA, S. H., SMITS, P. C., VAN DER GIESSEN, W. J. & DE FEYTER, P. J. (2004c) Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation, 109, 190-5.
  322. Unter-und Mittelstufe am Kaiser-Wilhelm-und Ratsgymnasium in Hannover 1991-1997
  323. WAKSMAN, R. (2006) Update on bioabsorbable stents: from bench to clinical. J Interv Cardiol, 19, 414-21.
  324. KEREIAKES, D. J., COX, D. A., HERMILLER, J. B., MIDEI, M. G., BACHINSKY, W. B., NUKTA, E. D., LEON, M. B., FINK, S., MARIN, L. & LANSKY, A. J. (2003) Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol, 92, 463-6.
  325. STREHBLOW, C., GYONGYOSI, M., SPERKER, W., SHIRAZI, M., WINDBERGER, U., PUGATSCH, T., BEN-SASSON, S., LOTAN, C. & GLOGAR, D. (2002) Usefulness of intravascular ultrasound-guided histological measurements after stenting in porcine coronary artery. Coron Artery Dis, 13, 291-4.
  326. SILBER, S. (2004) [When are drug-eluting stents effective? A critical analysis of the presently available data]. Z Kardiol, 93, 649-63.
  327. POUND, P., EBRAHIM, S., SANDERCOCK, P., BRACKEN, M. B. & ROBERTS, I. (2004) Where is the evidence that animal research benefits humans? BMJ, 328, 514-7.
  328. JAMES, S. K., STENESTRAND, U., LINDBACK, J., CARLSSON, J., SCHERSTEN, F., NILSSON, T., WALLENTIN, L. & LAGERQVIST, B. (2009) Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med, 360, 1933- 45.
  329. CHENG, J. M., ONUMA, Y., PIAZZA, N., NUIS, R. J., VAN DOMBURG, R. T. & SERRUYS, P. W. (2010) Comparison of five-year outcome of octogenarians undergoing percutaneous coronary intervention with drug-eluting versus bare-metal stents (from the RESEARCH and T-SEARCH Registries). Am J Cardiol, 106, 1376- 81.
  330. WESSELY, R., HAUSLEITER, J., MICHAELIS, C., JASCHKE, B., VOGESER, M., MILZ, S., BEHNISCH, B., SCHRATZENSTALLER, T., RENKE-GLUSZKO, M., STOVER, M., WINTERMANTEL, E., KASTRATI, A. & SCHOMIG, A. (2005) Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose-adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol, 25, 748-53.
  331. SCHOMIG, A., DIBRA, A., WINDECKER, S., MEHILLI, J., SUAREZ DE LEZO, J., KAISER, C., PARK, S. J., GOY, J. J., LEE, J. H., DI LORENZO, E., WU, J., JUNI, P., PFISTERER, M. E., MEIER, B. & KASTRATI, A. (2007) A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol, 50, 1373-80.
  332. LUSCHER, T. F., STEFFEL, J., EBERLI, F. R., JONER, M., NAKAZAWA, G., TANNER, F. C. & VIRMANI, R. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation, 115, 1051-8.
  333. NAKAZAWA, G., FINN, A. V., JONER, M., LADICH, E., KUTYS, R., MONT, E. K., GOLD, H. K., BURKE, A. P., KOLODGIE, F. D. & VIRMANI, R. (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation, 118, 1138-45.
  334. JONER, M., NAKAZAWA, G., FINN, A. V., QUEE, S. C., COLEMAN, L., ACAMPADO, E., WILSON, P. S., SKORIJA, K., CHENG, Q., XU, X., GOLD, H. K., KOLODGIE, F. D. & VIRMANI, R. (2008) Endothelial cell recovery between comparator polymer- based drug-eluting stents. J Am Coll Cardiol, 52, 333-42.
  335. O'NEILL, W. W. & LEON, M. B. (2003) Drug-eluting stents: costs versus clinical benefit. Circulation, 107, 3008-11.
  336. BYRNE, R. A., IIJIMA, R., MEHILLI, J., PINIECK, S., BRUSKINA, O., SCHOMIG, A. & KASTRATI, A. (2009) Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv, 2, 291-9.
  337. SERRUYS, P. W., DE JAEGERE, P., KIEMENEIJ, F., MACAYA, C., RUTSCH, W., HEYNDRICKX, G., EMANUELSSON, H., MARCO, J., LEGRAND, V., MATERNE, P. & ET AL. (1994) A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med, 331, 489-95.
  338. COEN, V., SERRUYS, P., SAUERWEIN, W., ORECCHIA, R., VON ROTTKAY, P., COUCKE, P., EHNERT, M., URBAN, P., BONAN, R. & LEVENDAG, P. (2003) Reno, a European postmarket surveillance registry, confirms effectiveness of coronary brachytherapy in routine clinical practice. Int J Radiat Oncol Biol Phys, 55, 1019-26.
  339. LEMOS, P. A., MOULIN, B., PERIN, M. A., OLIVEIRA, L. A., ARRUDA, J. A., LIMA, V. C., LIMA, A. A., CARAMORI, P. R., MEDEIROS, C. R., BARBOSA, M. R., BRITO, F. S., JR., RIBEIRO, E. E. & MARTINEZ, E. E. (2009) Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheter Cardiovasc Interv, 74, 665-73.
  340. ORMISTON, J. A., SERRUYS, P. W., REGAR, E., DUDEK, D., THUESEN, L., WEBSTER, M. W., ONUMA, Y., GARCIA-GARCIA, H. M., MCGREEVY, R. & VELDHOF, S. (2008) A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open- label trial. Lancet, 371, 899-907.
  341. KIRTANE, A. J., GUPTA, A., IYENGAR, S., MOSES, J. W., LEON, M. B., APPLEGATE, R., BRODIE, B., HANNAN, E., HARJAI, K., JENSEN, L. O., PARK, S. J., PERRY, R., RACZ, M., SAIA, F., TU, J. V., WAKSMAN, R., LANSKY, A. J., MEHRAN, R. & STONE, G. W. (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation, 119, 3198-206.
  342. SOUSA, J. E., COSTA, M. A., ABIZAID, A., SOUSA, A. G., FERES, F., MATTOS, L. A., CENTEMERO, M., MALDONADO, G., ABIZAID, A. S., PINTO, I., FALOTICO, R., JAEGER, J., POPMA, J. J. & SERRUYS, P. W. (2003a) Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three- dimensional intravascular ultrasound study. Circulation, 107, 24-7.
  343. SOUSA, J. E., COSTA, M. A., SOUSA, A. G., ABIZAID, A. C., SEIXAS, A. C., ABIZAID, A. S., FERES, F., MATTOS, L. A., FALOTICO, R., JAEGER, J., POPMA, J. J. & SERRUYS, P. W. (2003b) Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation, 107, 381-3.
  344. TANABE, K., SERRUYS, P. W., GRUBE, E., SMITS, P. C., SELBACH, G., VAN DER GIESSEN, W. J., STABEROCK, M., DE FEYTER, P., MULLER, R., REGAR, E., DEGERTEKIN, M., LIGTHART, J. M., DISCO, C., BACKX, B. & RUSSELL, M. E. (2003) TAXUS III Trial: in-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation, 107, 559- 64.
  345. SPAULDING, C., DAEMEN, J., BOERSMA, E., CUTLIP, D. E. & SERRUYS, P. W. (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 356, 989-97.
  346. SERRUYS, P. W., FOLEY, D. P., KIRKEEIDE, R. L. & KING, S. B., 3RD (1993) Restenosis revisited: insights provided by quantitative coronary angiography. Am Heart J, 126, 1243-67.
  347. DE FEYTER, P. J., DE JAEGERE, P. P. & SERRUYS, P. W. (1994) Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J, 127, 643-51.
  348. MORICE, M. C., SERRUYS, P. W., SOUSA, J. E., FAJADET, J., BAN HAYASHI, E., PERIN, M., COLOMBO, A., SCHULER, G., BARRAGAN, P., GUAGLIUMI, G., MOLNAR, F. & FALOTICO, R. (2002) A randomized comparison of a sirolimus- eluting stent with a standard stent for coronary revascularization. N Engl J Med, 346, 1773-80.
  349. WARDEH, A. J., KAY, I. P., SABATE, M., COEN, V. L., GIJZEL, A. L., LIGTHART, J. M., DEN BOER, A., LEVENDAG, P. C., VAN DER GIESSEN, W. J. & SERRUYS, P. W. (1999) beta-Particle-emitting radioactive stent implantation. A safety and feasibility study. Circulation, 100, 1684-9.
  350. DE FEYTER, P. J., KAY, P., DISCO, C. & SERRUYS, P. W. (1999) Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. Circulation, 100, 1777-83.
  351. SABATE, M., COSTA, M. A., KOZUMA, K., KAY, I. P., VAN DER GIESSEN, W. J., COEN, V. L., LIGTHART, J. M., SERRANO, P., LEVENDAG, P. C. & SERRUYS, P. W. (2000) Geographic miss: a cause of treatment failure in radio-oncology applied to intracoronary radiation therapy. Circulation, 101, 2467-71.
  352. RAIZNER, A. E., OESTERLE, S. N., WAKSMAN, R., SERRUYS, P. W., COLOMBO, A., LIM, Y. L., YEUNG, A. C., VAN DER GIESSEN, W. J., VANDERTIE, L., CHIU, J. K., WHITE, L. R., FITZGERALD, P. J., KALUZA, G. L. & ALI, N. M. (2000) Inhibition of restenosis with beta-emitting radiotherapy: Report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation, 102, 951-8.
  353. KAY, I. P., WARDEH, A. J., KOZUMA, K., FOLEY, D. P., KNOOK, A. H., THURY, A., SIANOS, G., VAN DER GIESSEN, W. J., LEVENDAG, P. C. & SERRUYS, P. W. (2001) Radioactive stents delay but do not prevent in-stent neointimal hyperplasia. Circulation, 103, 14-7.
  354. SOUSA, J. E., COSTA, M. A., ABIZAID, A., ABIZAID, A. S., FERES, F., PINTO, I. M., SEIXAS, A. C., STAICO, R., MATTOS, L. A., SOUSA, A. G., FALOTICO, R., JAEGER, J., POPMA, J. J. & SERRUYS, P. W. (2001a) Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation, 103, 192-5.
  355. SOUSA, J. E., COSTA, M. A., ABIZAID, A. C., RENSING, B. J., ABIZAID, A. S., TANAJURA, L. F., KOZUMA, K., VAN LANGENHOVE, G., SOUSA, A. G., FALOTICO, R., JAEGER, J., POPMA, J. J. & SERRUYS, P. W. (2001b) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation, 104, 2007-11.
  356. SERRUYS, P. W., DEGERTEKIN, M., TANABE, K., ABIZAID, A., SOUSA, J. E., COLOMBO, A., GUAGLIUMI, G., WIJNS, W., LINDEBOOM, W. K., LIGTHART, J., DE FEYTER, P. J. & MORICE, M. C. (2002) Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation, 106, 798-803.
  357. LASALA, J. M., COX, D. A., LEWIS, S. J., TADROS, P. N., HAAS, R. C., SCHWEIGER, M. J., CHHABRA, A., UNTEREKER, W. J., STARZYK, R. M., MASCIOLI, S. R., DAWKINS, K. D. & BAIM, D. S. (2009) Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme. EuroIntervention, 5, 67-77.
  358. KALTOFT, A., JENSEN, L. O., MAENG, M., TILSTED, H. H., THAYSSEN, P., BOTTCHER, M., LASSEN, J. F., KRUSELL, L. R., RASMUSSEN, K., HANSEN, K. N., PEDERSEN, L., JOHNSEN, S. P., SORENSEN, H. T. & THUESEN, L. (2009) 2-year clinical outcomes after implantation of sirolimus-eluting, paclitaxel-eluting, and bare-metal coronary stents: results from the WDHR (Western Denmark Heart Registry). J Am Coll Cardiol, 53, 658-64.
  359. GALLOE, A. M., THUESEN, L., KELBAEK, H., THAYSSEN, P., RASMUSSEN, K., HANSEN, P. R., BLIGAARD, N., SAUNAMAKI, K., JUNKER, A., AAROE, J., ABILDGAARD, U., RAVKILDE, J., ENGSTROM, T., JENSEN, J. S., ANDERSEN, H. R., BOTKER, H. E., GALATIUS, S., KRISTENSEN, S. D., MADSEN, J. K., KRUSELL, L. R., ABILDSTROM, S. Z., STEPHANSEN, G. B. & LASSEN, J. F. (2008) Comparison of paclitaxel-and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. JAMA, 299, 409-16.
  360. MOUSSA, I., DI MARIO, C., REIMERS, B., AKIYAMA, T., TOBIS, J. & COLOMBO, A. (1997) Subacute stent thrombosis in the era of intravascular ultrasound-guided coronary stenting without anticoagulation: frequency, predictors and clinical outcome. J Am Coll Cardiol, 29, 6-12.
  361. HILL, R. A., BOLAND, A., DICKSON, R., DUNDAR, Y., HAYCOX, A., MCLEOD, C., MUJICA MOTA, R., WALLEY, T. & BAGUST, A. (2007) Drug-eluting stents: a systematic review and economic evaluation. Health Technol Assess, 11, iii, xi-221.
  362. VANHOUTTE, P. M. (1989) Endothelium and control of vascular function. State of the Art lecture. Hypertension, 13, 658-67. VERSORGUNGSLEITLINIE, B. K. (Stand 08.09.2010) http://www.khk.versorgungsleitlinien.de/.
  363. MATSUMOTO, D., SHITE, J., SHINKE, T., OTAKE, H., TANINO, Y., OGASAWARA, D., SAWADA, T., PAREDES, O. L., HIRATA, K. & YOKOYAMA, M. (2007) Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur Heart J, 28, 961-7.
  364. YOUNG, S. G. & PARTHASARATHY, S. (1994) Why are low-density lipoproteins atherogenic? West J Med, 160, 153-64.
  365. GUYTON, J. R. & KLEMP, K. F. (1989) The lipid-rich core region of human atherosclerotic fibrous plaques. Prevalence of small lipid droplets and vesicles by electron microscopy. Am J Pathol, 134, 705-17.
  366. ROSS, R. (1993b) Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol, 143, 987-1002.
  367. JOHNSON-TIDEY, R. R., MCGREGOR, J. L., TAYLOR, P. R. & POSTON, R. N. (1994) Increase in the adhesion molecule P-selectin in endothelium overlying atherosclerotic plaques. Coexpression with intercellular adhesion molecule-1. Am J Pathol, 144, 952- 61.
  368. RIESSEN, R., ISNER, J. M., BLESSING, E., LOUSHIN, C., NIKOL, S. & WIGHT, T. N. (1994) Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. Am J Pathol, 144, 962-74.
  369. SIMIONESCU, N., VASILE, E., LUPU, F., POPESCU, G. & SIMIONESCU, M. (1986) Prelesional events in atherogenesis. Accumulation of extracellular cholesterol-rich liposomes in the arterial intima and cardiac valves of the hyperlipidemic rabbit. Am J Pathol, 123, 109-25.
  370. GERRITY, R. G. (1981a) The role of the monocyte in atherogenesis: I. Transition of blood- borne monocytes into foam cells in fatty lesions. Am J Pathol, 103, 181-90.
  371. GERRITY, R. G., NAITO, H. K., RICHARDSON, M. & SCHWARTZ, C. J. (1979) Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol, 95, 775-92.
  372. CASTELLOT, J. J., JR., ADDONIZIO, M. L., ROSENBERG, R. & KARNOVSKY, M. J. (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol, 90, 372-9.
  373. RIBICHINI, F., TOMAI, F., PALOSCIA, L., DI SCIASCIO, G., CAROSIO, G., ROMANO, M., VERNA, E., GALLI, M., TAMBURINO, C., DE CESARE, N., PIRISI, R., PISCIONE, F., LANTERI, G., FERRERO, V. & VASSANELLI, C. (2007) Steroid- eluting stents in patients with acute coronary syndrome: the dexamethasone eluting stent Italian registry. Heart, 93, 598-600.
  374. SERRUYS, P. & GERSHLICK, A. (2005) Handbook of Drug-Eluting Stents. Martin Dunitz pages.
  375. HAYASHI, S. I., YAMAMOTO, A., YOU, F., YAMASHITA, K., IKEGAME, Y., TAWADA, M., YOSHIMORI, T., SHIMIZU, S. & NAKASHIMA, S. (2009) The Stent-Eluting Drugs Sirolimus and Paclitaxel Suppress Healing of the Endothelium by Induction of Autophagy. Am J Pathol.
  376. PALINSKI, W., ROSENFELD, M. E., YLA-HERTTUALA, S., GURTNER, G. C., SOCHER, S. S., BUTLER, S. W., PARTHASARATHY, S., CAREW, T. E., STEINBERG, D. & WITZTUM, J. L. (1989) Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A, 86, 1372-6.
  377. HORIBA, M., KADOMATSU, K., NAKAMURA, E., MURAMATSU, H., IKEMATSU, S., SAKUMA, S., HAYASHI, K., YUZAWA, Y., MATSUO, S., KUZUYA, M., KANAME, T., HIRAI, M., SAITO, H. & MURAMATSU, T. (2000) Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J Clin Invest, 105, 489-95.
  378. SCHWARTZ, R. S., EDELMAN, E., VIRMANI, R., CARTER, A., GRANADA, J. F., KALUZA, G. L., CHRONOS, N. A., ROBINSON, K. A., WAKSMAN, R., WEINBERGER, J., WILSON, G. J. & WILENSKY, R. L. (2008) Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv, 1, 143-53.
  379. KUME, N. & GIMBRONE, M. A., JR. (1994) Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest, 93, 907-11.
  380. WATSON, K. E., BOSTROM, K., RAVINDRANATH, R., LAM, T., NORTON, B. & DEMER, L. L. (1994) TGF-beta 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest, 93, 2106-13.
  381. SCHWARTZ, D., ANDALIBI, A., CHAVERRI-ALMADA, L., BERLINER, J. A., KIRCHGESSNER, T., FANG, Z. T., TEKAMP-OLSON, P., LUSIS, A. J., GALLEGOS, C., FOGELMAN, A. M. & ET AL. (1994) Role of the GRO family of chemokines in monocyte adhesion to MM-LDL-stimulated endothelium. J Clin Invest, 94, 1968-73.
  382. MCMURRAY, H. F., PARTHASARATHY, S. & STEINBERG, D. (1993) Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest, 92, 1004-8.
  383. NAVAB, M., LIAO, F., HOUGH, G. P., ROSS, L. A., VAN LENTEN, B. J., RAJAVASHISTH, T. B., LUSIS, A. J., LAKS, H., DRINKWATER, D. C. & FOGELMAN, A. M. (1991) Interaction of monocytes with cocultures of human aortic wall cells involves interleukins 1 and 6 with marked increases in connexin43 message. J Clin Invest, 87, 1763-72.
  384. HAO, P. P., CHEN, Y. G., WANG, X. L. & ZHANG, Y. (2010) Efficacy and safety of drug- eluting stents in patients with acute ST-segment-elevation myocardial infarction: a meta-analysis of randomized controlled trials. Tex Heart Inst J, 37, 516-24.
  385. PERKINS, W. J., LANZINO, G. & BROTT, T. G. (2010) Carotid stenting vs endarterectomy: new results in perspective. Mayo Clin Proc, 85, 1101-8.
  386. YLA-HERTTUALA, S., PALINSKI, W., ROSENFELD, M. E., PARTHASARATHY, S., CAREW, T. E., BUTLER, S., WITZTUM, J. L. & STEINBERG, D. (1989) Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest, 84, 1086-95.
  387. KUME, N., CYBULSKY, M. I. & GIMBRONE, M. A., JR. (1992) Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest, 90, 1138-44.
  388. WOLFBAUER, G., GLICK, J. M., MINOR, L. K. & ROTHBLAT, G. H. (1986) Development of the smooth muscle foam cell: uptake of macrophage lipid inclusions. Proc Natl Acad Sci U S A, 83, 7760-4.
  389. SPARROW, C. P., PARTHASARATHY, S. & STEINBERG, D. (1989) A macrophage receptor that recognizes oxidized low density lipoprotein but not acetylated low density lipoprotein. J Biol Chem, 264, 2599-604.
  390. POON, M., MARX, S. O., GALLO, R., BADIMON, J. J., TAUBMAN, M. B. & MARKS, A. R. (1996) Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest, 98, 2277-83.
  391. CUSHING, S. D., BERLINER, J. A., VALENTE, A. J., TERRITO, M. C., NAVAB, M., PARHAMI, F., GERRITY, R., SCHWARTZ, C. J. & FOGELMAN, A. M. (1990) Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A, 87, 5134-8.
  392. RESNICK, N., COLLINS, T., ATKINSON, W., BONTHRON, D. T., DEWEY, C. F., JR. & GIMBRON, M. A., JR. (1993a) Platelet-derived growth factor B chain promoter contains a cis-acting fluid shear-stress-responsive element. Proc Natl Acad Sci U S A, 90, 7908.
  393. NEUMANN, F. J., DESMET, W., GRUBE, E., BRACHMANN, J., PRESBITERO, P., RUBARTELLI, P., MUGGE, A., DI PEDE, F., FULLGRAF, D., AENGEVAEREN, W., SPEDICATO, L. & POPMA, J. J. (2005) Effectiveness and safety of sirolimus- eluting stents in the treatment of restenosis after coronary stent placement. Circulation, 111, 2107-11.
  394. SERRUYS, P. W., GARG, S., ABIZAID, A., ORMISTON, J., WINDECKER, S., VERHEYE, S., DUBOIS, C., STEWART, J., HAUPTMANN, K. E., SCHOFER, J., STANGL, K., WITZENBICHLER, B., WIEMER, M., BARBATO, E., DE VRIES, T., DEN DRIJVER, A. M., OTAKE, H., MEREDITH, L., TOYLOY, S. & FITZGERALD, P. (2010a) A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. EuroIntervention, 6, 195-205.

* Das Dokument ist im Internet frei zugänglich - Hinweise zu den Nutzungsrechten
© UB Marburg 1997 - 2024 Universitätsbibliothek Marburg